nedaplatin profile

nedaplatin: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	72120
MeSH ID	M0152723
PubMed CID	131842090
MeSH ID	M0152723

Synonym
AC-1433
cis-diammine(glycolato)platinum
NCGC00181152-01
platinum,o(2)]-, (sp-4-3)-
platinum,o(2))-, (sp-4-3)-
nsc375101
nsc-375101
platinum, diammine(hydroxy-kappao)acetato(2-)-kappao)-, (sp-4-3)-
cis-diammine (glycolato)platinum
nedaplatin [inn]
ccris 4088
platinum, diammine(hydroxyacetato(2-)-o(sup 1),o(sup 2))-, (sp-4-3)-
cis-diammine(glycolato-o(sup 1),o(sup 2))platinum
aqupla (tn)
D01416
nedaplatin (jan/inn)
cas-95734-82-0
tox21_112756
dtxcid6026878
unii-8uq3w6jxan
8uq3w6jxan ,
AKOS015854028
nedaplatin
95734-82-0
dtxsid8046878 ,
platinum(2+) azanide- hydroxyacetic acid(1:2:1)
HY-13700
(sp-4-3)-diammine[2-(hydroxy-\|eo)acetato(2-)-\|eo]platinum

Excerpt	Reference	Relevance
"A clinical investigation of adverse events was conducted to confirm the safety of concurrent chemotherapy using nedaplatin (cisplatin derivative) and radiotherapy in the high-risk carcinoma of the uterine cervix."	( [Concurrent chemoradiation therapy with nedaplatin for high-risk cervical cancer--clinical investigation of adverse events]. Hashimoto, N; Kamiura, S; Kobayashi, K; Ohira, H; Saji, F; Samejima, Y; Sawai, K; Seino, H, 2001)	0.31
"In conclusion, this study indicates that combination chemoradiotherapy with nedaplatin and 5-FU is safe and efficacious for patients with advanced esophageal carcinomas."	( Efficacy and toxicity of nedaplatin and 5-FU with radiation treatment for advanced esophageal carcinomas. Fukai, Y; Fukuchi, M; Kato, H; Kuwano, H; Manda, R; Masuda, N; Miyazaki, T; Nakajima, M; Sohda, M; Tsukada, K, )	0.13
"The side effect of anticancer agents such as nausea and vomiting frequently interrupt chemotherapy."	( [Effect of steroid on antiemetic for side effect of anticancer chemotherapy]. Matsumoto, T; Mikami, T; Momokawa, K; Nakamura, Y; Sakayauchi, T; Sasaki, T; Watanabe, T, 2005)	0.33
" The main adverse events were hematological toxicity, mucositis and dermatitis."	( Efficacy and toxicity of concurrent chemoradiotherapy with nedaplatin and S-1 for head and neck cancer. Murai, M; Ohashi, T; Ohnishi, M; Tanahashi, S, 2011)	0.37
" However, each agent differs in its efficacy and adverse effects, although the molecular mechanism involved is unclear."	( Organic cation transporter OCT/SLC22A and H(+)/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents. Inui, K; Yonezawa, A, 2011)	0.37
" However, serious adverse events have been reported after platinum-based chemotherapy treatment for LACC patients."	( The toxicity and long-term efficacy of nedaplatin and paclitaxel treatment as neoadjuvant chemotherapy for locally advanced cervical cancer. Chen, X; Li, H; Li, K; Li, X; Liu, Y; Lou, G; Yin, M; Zhang, H, 2012)	0.38
" The incidences of toxic reactions for NP and PC were 32."	( The toxicity and long-term efficacy of nedaplatin and paclitaxel treatment as neoadjuvant chemotherapy for locally advanced cervical cancer. Chen, X; Li, H; Li, K; Li, X; Liu, Y; Lou, G; Yin, M; Zhang, H, 2012)	0.38
"NP NACT followed by radical hysterectomy offers a higher response rate, lower incidence of toxic reactions and better long-term DFS and OS for patients with LACC compared with the chemotherapy regimen of PC followed by radical hysterectomy."	( The toxicity and long-term efficacy of nedaplatin and paclitaxel treatment as neoadjuvant chemotherapy for locally advanced cervical cancer. Chen, X; Li, H; Li, K; Li, X; Liu, Y; Lou, G; Yin, M; Zhang, H, 2012)	0.38
"7%) patients, but no other serious adverse effects were detected."	( [Efficacy and safety of biweekly nedaplatin in combination with docetaxel as second-line chemotherapy in patients with unresectable or recurrent esophageal cancer]. Egawa, T; Eto, E; Inaba, Y; Irino, T; Ito, Y; Kenmochi, T; Mihara, K; Murakawa, M; Nagashima, A; Okamura, A, 2011)	0.37
"Replacing carboplatin with nedaplatin provided a safe and efficacious approach to manage carboplatin hypersensitivity."	( Safety and efficacy of substituting nedaplatin after carboplatin hypersensitivity reactions in gynecologic malignancies. Matsumoto, K; Michikami, H; Minaguchi, T; Ochi, H; Okada, S; Oki, A; Onuki, M; Satoh, T; Yoshikawa, H, 2013)	0.39
"There have been no case reports of the risk of serious adverse events associated with the administration of irinotecan hydrochloride (CPT-11) in patients with gynecologic cancer who are compound heterozygous for UGT1A16 and UGT1A128."	( Recurrent cervical cancer in a patient who was compound heterozygous for UGT1A16 and UGT1A128 presenting with serious adverse events during irinotecan hydrochloride/nedaplatin therapy. Miura, Y; Shoji, T; Sugiyama, T; Takatori, E; Takeuchi, S; Yoshizaki, A, 2013)	0.39
" Grade 3-4 adverse events included leukopenia (2/39), and neutropenia (3/39) in first-line therapy versus neutropenia (1/40) and thrombocytopenia (2/40) in second-line treatment."	( A retrospective analysis of efficacy and safety of adding bevacizumab to chemotherapy as first- and second-line therapy in advanced non-small-cell lung cancer (NSCLC). Chen, N; Fang, W; Hu, Z; Huang, J; Quan, R; Zhan, J; Zhang, H; Zhang, L; Zhou, T, 2016)	0.43
"To compare the time-to-treatment failure (TTF), overall survival (OS), overall response rate (ORR), and adverse effects of regimens including nedaplatin- or cisplatin-based chemotherapy for advanced breast cancer (ABC)."	( Efficacy and Safety of Nedaplatin in Advanced Breast Cancer Therapy. Cai, L; Chen, X; Dong, X; Feng, T; Lu, H; Meng, Q; Pang, H; Shen, Q, 2016)	0.43
" We analyzed the clinical response, survival rate, acute adverse events, and late swallowing toxicity."	( Long-term efficacy and toxicity of concurrent chemoradiotherapy with nedaplatin and S-1 for head and neck squamous cell carcinoma. Ohashi, T; Ohnishi, M; Okuda, H; Takada, N; Takagi, C; Takahashi, H, 2019)	0.51
" The main acute adverse events were leukopenia, neutropenia, mucositis, and dermatitis."	( Long-term efficacy and toxicity of concurrent chemoradiotherapy with nedaplatin and S-1 for head and neck squamous cell carcinoma. Ohashi, T; Ohnishi, M; Okuda, H; Takada, N; Takagi, C; Takahashi, H, 2019)	0.51
" The main toxic side effect of the patients was gastrointestinal reaction in both groups."	( The efficacy and safety of irinotecan combined with nedaplatin in the treatment of small cell lung cancer. Fang, S; Fu, J; Wang, D; Wang, Y; Wen, Y; Yin, X, )	0.13
"Cisplatin(CDDP)is a key drug for head and neck cancer therapy, but frequently induces severe adverse events including renal dysfunction."	( Survey of the Time-Onset Profiles of Nedaplatin-Induced Adverse Events in Head and Neck Cancer Therapy. Hoshi, A; Kobayashi, H; Kurihara, T; Momo, K; Sasaki, T; Shimane, T, 2021)	0.62
" Laboratory-based adverse events(WBC, Hb, platelet[Plt], SCr, Alb)and oral mucositis were assessed according to CTCAE v5."	( Survey of the Time-Onset Profiles of Nedaplatin-Induced Adverse Events in Head and Neck Cancer Therapy. Hoshi, A; Kobayashi, H; Kurihara, T; Momo, K; Sasaki, T; Shimane, T, 2021)	0.62
"3%) experienced treatment-related adverse events (TRAE), among which 8 (57."	( Efficacy and Safety of the PD-1 Inhibitor Combined with Albumin-Bound Paclitaxel and Nedaplatin in Preoperative Neoadjuvant Therapy of Unresectable Stage III Lung Squamous Cell Carcinoma. Li, L; Song, C; Sun, Z; Wang, W; Xu, H; Yin, J, 2022)	0.72

Excerpt	Reference	Relevance
" The Cmax and AUC of active 254-S in plasma determined by bioassay following an intraperitoneal infusion were about 60% and 60-80% of those following an intravenous infusion, respectively."	( [Pharmacokinetics of cis-diammine (glycolato) platinum (254-S), a new platinum antitumor agent, following an intravenous and intraperitoneal infusion bioactive platinum concentration profile]. Hirabayashi, K; Oguma, T; Okada, E; Shimamura, K, 1990)	0.28
" This similarity in side effects may mainly be due to the comparable pharmacokinetic behavior of these two platinum compounds."	( Pharmacokinetics of (glycolate-0,0')-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin. Bungo, M; Eguchi, K; Fujiwara, Y; Fukuda, M; Horichi, N; Niimi, S; Ohe, Y; Sasaki, Y; Shinkai, T; Tamura, T, 1989)	0.28
" The plasma concentrations of ultrafilterable platinum were similar to those of total platinum and there was little difference in the pharmacokinetic parameters between total platinum and ultrafilterable platinum."	( Pharmacokinetics of platinum in cancer patients following intravenous infusion of cis-diammine(glycolato)platinum, 254-S. Oguma, T; Ota, K; Shimamura, K, )	0.13
" The total platinum showed the opposite pharmacokinetic behavior."	( Pharmacokinetic evaluation of (glycolato-O,O')diammine platinum(II) in lung lymph in sheep. Amari, T; Fujimoto, K; Hayano, T; Kobayashi, T; Koizumi, T; Koyama, S; Kubo, K; Sakai, R; Sekiguchi, M; Shinozaki, S, 1993)	0.29
"We undertook a pharmacokinetic comparison between cisplatin and nedaplatin in hepatic arterial chemotherapy using complete hepatic venous isolation and charcoal hemoperfusion (HVI."	( [Pharmacokinetic comparison between cisplatin and nedaplatin in hepatic arterial chemotherapy using complete hepatic venous isolation and charcoal hemoperfusion]. Ku, Y; Kuroda, Y; Muramatsu, S, 1998)	0.3
"The pharmacodynamic effects of cis-diammine(glycolato)platinum (nedaplatin, 254-S) in vitro have been reported, but the dosage and exposure time in vitro have not always been based on clinical observations of the drug's actions in vivo."	( Cytocidal effect and DNA damage of nedaplatin in vitro by simulating pharmacokinetic parameters. Hongo, A; Kawanishi, K; Kodama, J; Kudo, T; Miyagi, Y; Nakamura, K; Yamamoto, J; Yoshinouchi, M, 2001)	0.31
" A colony-formation assay for the surviving fraction and an alkaline-elution assay for DNA crosslink measurement were done for the pharmacodynamic evaluation with comparison on the basis of the AUC value."	( Cytocidal effect and DNA damage of nedaplatin in vitro by simulating pharmacokinetic parameters. Hongo, A; Kawanishi, K; Kodama, J; Kudo, T; Miyagi, Y; Nakamura, K; Yamamoto, J; Yoshinouchi, M, 2001)	0.31
"In order to clarify the pharmacokinetic profile of nedaplatin, unbound platinum concentrations (789 points) in plasma after intravenous infusion of nedaplatin were obtained from 183 courses for 141 patients."	( Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients. Ishibashi, T; Oguma, T; Yano, Y, 2003)	0.32
"A two-compartment pharmacokinetic model with zero-order input and first order elimination described the current data well."	( Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients. Ishibashi, T; Oguma, T; Yano, Y, 2003)	0.32
"A population pharmacokinetic model was developed for unbound platinum after intravenous infusion of nedaplatin."	( Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients. Ishibashi, T; Oguma, T; Yano, Y, 2003)	0.32
"We performed a pharmacokinetic phase I trial of the combination of S-1 granules and nedaplatin for head and neck squamous cell carcinoma (HNSCC)."	( Phase I pharmacokinetic study of S-1 granules and nedaplatin for advanced head and neck cancer. Doi, K; Fujisaka, Y; Hayashi, H; Kawakami, H; Nakagawa, K; Nishimura, Y; Nishina, S; Okamoto, I; Okamoto, K; Satoh, T; Takeda, M; Tanaka, K; Terao, K; Ueda, S, 2013)	0.39
" Pharmacokinetic parameters of S-1 granule did not differ from the capsula formulation."	( Phase I pharmacokinetic study of S-1 granules and nedaplatin for advanced head and neck cancer. Doi, K; Fujisaka, Y; Hayashi, H; Kawakami, H; Nakagawa, K; Nishimura, Y; Nishina, S; Okamoto, I; Okamoto, K; Satoh, T; Takeda, M; Tanaka, K; Terao, K; Ueda, S, 2013)	0.39

Excerpt	Reference	Relevance
" In this study the antitumor effect of 254-S combined with hyperthermia in vivo in mice was studied."	( Enhancement of antitumor effects of new analogue of platinum, cis-diammine (glycolato) platinum (254-S) combined with hyperthermia in vivo. Jo, A; Mizuuchi, H; Sakurai, K; Takada, K; Tsumura, M; Yoshiga, K, )	0.13
"A series of patients with esophageal cancer was treated with chemotherapeutic regimens of the new antitumor platinum preparation nedaplatin plus 5-FU in combination with radiation therapy, and the therapeutic responses, side effects, and complications were clinically assessed."	( Nedaplatin and 5-FU combined with radiation in the treatment for esophageal cancer. Asai, A; Hioki, K; Michiura, T; Mori, T; Motohiro, T; Yamanaka, H, 1998)	0.3
" The chemotherapy consisted of protracted infusion of 5-fluorouracil (5-FU), combined with infusion of nedaplatin (NDP)."	( [A case of esophageal carcinoma with multiple liver metastases successfully treated with nedaplatin (NDP) and 5-fluorouracil (5-FU) combined with radiotherapy]. Eguchi, J; Ito, H; Ito, T; Kaneko, K; Kitahara, T; Konishi, K; Kurahashi, T; Mitamura, K; Yamamoto, T, 2001)	0.31
" Ten patients were treated with chemotherapy by superselective intraarterial infusion of CDGP combined with radiotherapy."	( [Chemotherapy by superselective intraarterial infusion of nedaplatin combined with radiotherapy for oral cancer]. Goto, M; Katsuki, T; Yamashita, Y, 2002)	0.31
"From January 1999 to November 2000, a total of 24 esophageal cancer patients (17 untreated and 7 recurrent cases) were treated with radiation therapy (60-70 Gy) combined with cis-diammine-glycolatoplatinum (Nedaplatin) (80-120 mg/body) and 5-fluorouracil (5-FU) (500-1,000 mg/body/24 h, continuous infusion for 5 days)."	( Radiation therapy combined with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for untreated and recurrent esophageal cancer. Britton, KR; Matsushita, H; Miyata, T; Miyazaki, S; Nemoto, K; Ogawa, Y; Takahashi, C; Takai, Y; Takeda, K; Yamada, S, 2003)	0.32
" One course of nedaplatin, 5-FU and LV combined with radiation was performed alternatively."	( [Effect of nedaplatin, 5-FU, and leucovorin combined with radiation therapy in unresectable esophageal carcinoma]. Futami, R; Makino, H; Maruyama, H; Miyashita, M; Miyashita, T; Nomura, T; Sasajima, K; Tajiri, T; Tateno, A, 2003)	0.32
"We conducted a pilot study of nedaplatin + 5-fluorouracil (5-FU) combined with radiotherapy for 29 patients with primary advanced (stage IV) esophageal cancer."	( [Nedaplatin and 5-fluorouracil combined with radiotherapy for advanced esophageal cancer]. Eguchi, R; Hayashi, K; Ide, H; Mitsuhashi, M; Nakamura, T; Narumiya, K; Ota, M; Takasaki, K, 2003)	0.32
" This regimen is under way in which chemotherapy with 5-FU 500 mg/day on days 1 to 5 and superselective intra-arterial infusion of CDGP on day 6 combined with radiation therapy is being evaluated for locally advanced oral cancer."	( [Clinical trial of chemotherapy by superselective intra-arterial infusion of nedaplatin combined with radiotherapy for advanced oral cancer]. Goto, M; Shikimori, M; Yamshita, Y, 2005)	0.33
"To evaluate the treatment outcome of radiotherapy combined with cis-diammine-glycolatoplatinum (nedaplatin) plus 5-fluorouracil (5-FU) for esophageal cancer."	( Radiation therapy combined with cis-diammine-glycolatoplatinum (nedaplatin) and 5-fluorouracil for Japanese stage II-IV esophageal cancer compared with cisplatin plus 5-fluorouracil regimen: a retrospective study. Igaki, H; Nakagawa, K; Nakamura, N; Ohtomo, K; Sasano, N; Shiraishi, K; Tago, M; Yamashita, H, 2006)	0.33
" The purpose of the present study was to evaluate the effectiveness and safety of radiotherapy combined with nedaplatin and 5-FU for postoperative locoregional (excluding hematogenous metastasis) recurrent esophageal cancer."	( Results of radiation therapy combined with nedaplatin (cis-diammine-glycoplatinum) and 5-fluorouracil for postoperative locoregional recurrent esophageal cancer. Jingu, K; Matsushita, H; Nakata, E; Nemoto, K; Ogawa, Y; Sugawara, T; Takahashi, C; Takai, Y; Yamada, S, 2006)	0.33
"In June 2000, we started a phase II study on treatment of postoperative locoregional recurrent esophageal cancer with radiotherapy (60 Gy/30 fr/6 weeks) combined with chemotherapy consisting of two cycles of nedaplatin (70 mg/m2/2 h) and 5-FU (500 mg/m2/24 h for 5 days)."	( Results of radiation therapy combined with nedaplatin (cis-diammine-glycoplatinum) and 5-fluorouracil for postoperative locoregional recurrent esophageal cancer. Jingu, K; Matsushita, H; Nakata, E; Nemoto, K; Ogawa, Y; Sugawara, T; Takahashi, C; Takai, Y; Yamada, S, 2006)	0.33
"Radiotherapy combined with nedaplatin and 5-FU is a safe and effective salvage treatment for postoperative locoregional recurrent esophageal cancer."	( Results of radiation therapy combined with nedaplatin (cis-diammine-glycoplatinum) and 5-fluorouracil for postoperative locoregional recurrent esophageal cancer. Jingu, K; Matsushita, H; Nakata, E; Nemoto, K; Ogawa, Y; Sugawara, T; Takahashi, C; Takai, Y; Yamada, S, 2006)	0.33
"To investigate the therapeutic effect, long term survival and side effect on NSCLC patients treated with nadaplatin combined with paclitaxol and cisplatin combined with paclitaxol."	( [Nadaplatin or cisplatin combined with paclitaxol in treatment for non-small cell lung cancer: a randomized controlled study]. Chen, LK; Guan, ZZ; Hang, Y; Xu, GC; Yang, QY, 2007)	0.34
"Nadaplatin combined with paclitaxol is an effective treatment regimen for NSCLC patients."	( [Nadaplatin or cisplatin combined with paclitaxol in treatment for non-small cell lung cancer: a randomized controlled study]. Chen, LK; Guan, ZZ; Hang, Y; Xu, GC; Yang, QY, 2007)	0.34
"To investigate the efficacy and toxicity of nedaplatin combined with tegafur in the treatment for patients with advanced esophageal cancer."	( [Nedaplatin combined with tegafur in the treatment for advanced esophageal cancer]. Chen, XB; Fan, QX; Geng, L; Han, JW; Jiao, ZM; Lu, P; Lu, SP; Lu, TY; Luo, SX; Ma, ZY; Song, M; Wang, GJ; Wang, JS; Wang, R; Wang, RL; Wu, XA; Zhang, MZ; Zhao, YF, 2008)	0.35
"The regimen of nedaplatin combined with tegafur is effective and tolerable for the treatment of advanced esophageal cancer."	( [Nedaplatin combined with tegafur in the treatment for advanced esophageal cancer]. Chen, XB; Fan, QX; Geng, L; Han, JW; Jiao, ZM; Lu, P; Lu, SP; Lu, TY; Luo, SX; Ma, ZY; Song, M; Wang, GJ; Wang, JS; Wang, R; Wang, RL; Wu, XA; Zhang, MZ; Zhao, YF, 2008)	0.35
"To study the anti-tumor effect of Tetrandrine (Tet) combined with Nedaplatin (Nap) on the human liver cancer cell line 7402, and explore its mechanism."	( [The study of anti-tumor effect of Tetrandrine combined with Nedaplatin on human liver cancer cell line 7402]. Chen, XB; Deng, WY; Han, LL; Li, N; Luo, SX; Zhou, MQ, 2008)	0.35
"Compared with Tet or Nap individual drug groups, Tet combined with Nap obviously increased the inhibitatory rate and apoptosis rate of the human liver cancer cell line 7402."	( [The study of anti-tumor effect of Tetrandrine combined with Nedaplatin on human liver cancer cell line 7402]. Chen, XB; Deng, WY; Han, LL; Li, N; Luo, SX; Zhou, MQ, 2008)	0.35
"Tet combined with Nap can obviously increase apoptosis-inducing effect, and its mechanism may be regulating cell cycle and increasing apoptosis-inducing effect which is regulated by several genes."	( [The study of anti-tumor effect of Tetrandrine combined with Nedaplatin on human liver cancer cell line 7402]. Chen, XB; Deng, WY; Han, LL; Li, N; Luo, SX; Zhou, MQ, 2008)	0.35
"Protracted low-dose concurrent chemotherapy combined with radiation has been proposed for enhanced treatment results for esophageal cancer."	( Prospective study of daily low-dose nedaplatin and continuous 5-fluorouracil infusion combined with radiation for the treatment of esophageal squamous cell carcinoma. Furuta, T; Hamaya, Y; Ikuma, M; Iwaizumi, M; Kanaoka, S; Kodaira, C; Kosugi, T; Nishino, M; Osawa, S; Sugimoto, K; Takagaki, K; Takayanagi, Y; Terai, T; Yamada, T; Yamade, M; Yoshida, K, 2009)	0.35
" Radiation therapy combined with nedaplatin and 5-FU is a safe and effective method for treating cT4 advanced esophageal cancer."	( [A case of stage IV advanced esophageal cancer with a long term survival by radiation therapy combined with nedaplatin and 5-FU chemotherapy]. Dan, N; Hirakawa, K; Kubo, N; Morimoto, J; Muguruma, K; Nishiguchi, Y; Oohira, M; Sawada, T; Tanaka, H; Yamashita, Y; Yashiro, M, 2009)	0.35
" We conducted this study to investigate its efficacy and safety when combined with chemotherapy in patients with advanced solid tumors."	( Efficacy and safety of endostar combined with chemotherapy in patients with advanced solid tumors. Huang, XE; Jiang, Y; Li, Y; Xiang, J; Yan, PW, 2010)	0.36
"5 mg/m2 /day as an intravenous infusion for more than 7 days, in combination with chemotherapy."	( Efficacy and safety of endostar combined with chemotherapy in patients with advanced solid tumors. Huang, XE; Jiang, Y; Li, Y; Xiang, J; Yan, PW, 2010)	0.36
"Our study revealed that toxicity of Endostar combined with chemotherapy in the treatment of solid tumors was tolerable with moderate efficacy."	( Efficacy and safety of endostar combined with chemotherapy in patients with advanced solid tumors. Huang, XE; Jiang, Y; Li, Y; Xiang, J; Yan, PW, 2010)	0.36
"To compare the curative effect, safety and survival of Nedaplatin combined with docetaxel and docetaxel alone as a second line treatment for advanced NSCLC."	( [Comparison of the efficacy of nedaplatin combined with docetaxel and docetaxel alone as a second line treatment for advanced non-small cell lung cancer]. Chen, ZW; Gu, LP; Shen, SP, 2010)	0.36
"From Sep 2005 to Mar 2009, fifty-eight patients with NSCLC treated in the Shanghai Chest Hospital who failed first-line chemotherapy and receiving docetaxel or docetaxel combined with nedaplatin were retrospectively analyzed."	( [Comparison of the efficacy of nedaplatin combined with docetaxel and docetaxel alone as a second line treatment for advanced non-small cell lung cancer]. Chen, ZW; Gu, LP; Shen, SP, 2010)	0.36
"Compared with the treatment with docetaxel alone, Nedaplatin combined with docetaxel as a second line treatment for NSCLC has a better curative effect and acceptable toxicity."	( [Comparison of the efficacy of nedaplatin combined with docetaxel and docetaxel alone as a second line treatment for advanced non-small cell lung cancer]. Chen, ZW; Gu, LP; Shen, SP, 2010)	0.36
"Although zoledronic acid (ZOL) has been reported to inhibit bone metastasis from lung cancer, the optimum chemotherapy regimen in combination with ZOL has not yet been determined."	( A feasibility study of zoledronic acid combined with carboplatin/nedaplatin plus paclitaxel in patients with non-small cell lung cancer with bone metastases. Adachi, M; Hirama, M; Hirose, T; Ishiwata, T; Iwakami, S; Miura, K; Takahashi, K; Tominaga, S, )	0.13
"Eighteen patients having non-small cell lung cancer (NSCLC) with bone metastasis who received carboplatin/nedaplatin plus paclitaxel combined with ZOL (4 mg every 28 days) were enrolled to investigate the feasibility of this treatment."	( A feasibility study of zoledronic acid combined with carboplatin/nedaplatin plus paclitaxel in patients with non-small cell lung cancer with bone metastases. Adachi, M; Hirama, M; Hirose, T; Ishiwata, T; Iwakami, S; Miura, K; Takahashi, K; Tominaga, S, )	0.13
"ZOL combined with carboplatin/nedaplatin plus paclitaxel is an effective and tolerable treatment for NSCLC with bone metastases."	( A feasibility study of zoledronic acid combined with carboplatin/nedaplatin plus paclitaxel in patients with non-small cell lung cancer with bone metastases. Adachi, M; Hirama, M; Hirose, T; Ishiwata, T; Iwakami, S; Miura, K; Takahashi, K; Tominaga, S, )	0.13
" We have treated with biweekly nedaplatin (CDGP 40 mg/m²) in combination with docetaxe (l DOC 30 mg/m²) as second-line chemotherapy and investigated its efficacy and safety."	( [Efficacy and safety of biweekly nedaplatin in combination with docetaxel as second-line chemotherapy in patients with unresectable or recurrent esophageal cancer]. Egawa, T; Eto, E; Inaba, Y; Irino, T; Ito, Y; Kenmochi, T; Mihara, K; Murakawa, M; Nagashima, A; Okamura, A, 2011)	0.37
"To investigate the early efficacy of nedaplatin combined with megestrol in concurrent chemoradiotherapy for advanced cervical cancer."	( [Analysis of the initial efficacy of nedaplatin combined with megestrol in concurrent chemoradiotherapy for advanced cervical cancer]. Ke, QH; Liu, Z; Su, XY; Yang, JY; Zhang, WT; Zhou, SQ, 2011)	0.37
" The purpose of the present study was to update the results of radiotherapy combined with nedaplatin and 5-fluorouracil (5-FU) for postoperative loco-regional recurrent esophageal cancer."	( Long-term results of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study. Abe, K; Ishikawa, Y; Jingu, K; Kubozono, M; Matsushita, H; Nemoto, K; Shirata, Y; Sugawara, T; Takahashi, C; Takeda, K; Tanabe, T; Umezawa, R; Yamamoto, T, 2012)	0.38
"Between 2000 and 2004, we performed a phase II study on treatment of postoperative loco-regional recurrent esophageal cancer with radiotherapy (60 Gy/30 fractions/6 weeks) combined with chemotherapy consisting of two cycles of nedaplatin (70 mg/m2/2 h) and 5-FU (500 mg/m2/24 h for 5 days)."	( Long-term results of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study. Abe, K; Ishikawa, Y; Jingu, K; Kubozono, M; Matsushita, H; Nemoto, K; Shirata, Y; Sugawara, T; Takahashi, C; Takeda, K; Tanabe, T; Umezawa, R; Yamamoto, T, 2012)	0.38
"Radiotherapy combined with nedaplatin and 5-FU is a safe and effective salvage treatment for postoperative loco-regional recurrent esophageal cancer."	( Long-term results of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study. Abe, K; Ishikawa, Y; Jingu, K; Kubozono, M; Matsushita, H; Nemoto, K; Shirata, Y; Sugawara, T; Takahashi, C; Takeda, K; Tanabe, T; Umezawa, R; Yamamoto, T, 2012)	0.38
" A multicenter phase II study was conducted to evaluate the efficacy and toxicity of capecitabine combined with nedaplatin for these patients."	( Multicenter phase II study of capecitabine combined with nedaplatin for recurrent and metastatic nasopharyngeal carcinoma patients after failure of cisplatin-based chemotherapy. Chen, ZB; Liao, H; Lin, Z; Ou, XQ; Peng, PJ; Peng, YL; Wang, SY; Zhang, HY, 2013)	0.39
"Capecitabine combined with nedaplatin offers a satisfactory clinical activity and an acceptable safety profile for recurrent and metastatic nasopharyngeal carcinoma patients after failure of cisplatin-based chemotherapy."	( Multicenter phase II study of capecitabine combined with nedaplatin for recurrent and metastatic nasopharyngeal carcinoma patients after failure of cisplatin-based chemotherapy. Chen, ZB; Liao, H; Lin, Z; Ou, XQ; Peng, PJ; Peng, YL; Wang, SY; Zhang, HY, 2013)	0.39
" Therefore we evaluate the efficacy and safety of irinotecan in combination with nedaplatin/cisplatin against refractory or relapsed small cell lung cancer."	( [A retrospective study of the efficacy and toxicity of irinotecan in combination with nedaplatin versus irinotecan in combination with cisplatin as salvage treatment in refractory or relapsed small cell lung cancer]. Hao, X; Hu, X; Li, J; Shi, Y; Wang, H; Wang, Y; Xu, J; Yu, S; Zhang, X, 2013)	0.39
" Our chemoradiotherapy protocol was as follows: (i) alternating chemoradiotherapy with 5-fluorouracil and nedaplatin; (ii) whole pelvic radiotherapy with the dynamic conformal technique combined with intracavitary brachytherapy; (iii) prophylactic irradiation to the para-aortic region for International Federation of Gynecology and Obstetrics III/IVA or positive pelvic node and full-dose radiotherapy for positive para-aortic node."	( Clinical efficacy of alternating chemoradiotherapy by conformal radiotherapy combined with intracavitary brachytherapy for high-risk cervical cancer. Fuwa, N; Hirata, K; Ito, J; Kodaira, T; Nakanishi, T; Ohshima, Y; Tachibana, H; Tomita, N, 2014)	0.4
"Both nedaplatin and oxaliplatin combined with paclitaxel or docetaxel have demonstrated potent activity in advanced non-small cell lung cancer (NSCLC) patients, but there is no study comparing the difference between these 2 chemotherapy regimens."	( Nedaplatin or oxaliplatin combined with paclitaxel and docetaxel as first-line treatment for patients with advanced non-small cell lung cancer. Liang, H; Liu, E; Pan, F; Qin, H; Ruan, Z; Zhang, K, 2014)	0.4
" They all received nedaplatin (80 mg/m2, nedaplatin group) or oxaliplatin (130 mg/m2, oxaliplatin group) combined with paclitaxel (175 mg/m2) or docetaxel (75 mg/m2) as first-line treatment."	( Nedaplatin or oxaliplatin combined with paclitaxel and docetaxel as first-line treatment for patients with advanced non-small cell lung cancer. Liang, H; Liu, E; Pan, F; Qin, H; Ruan, Z; Zhang, K, 2014)	0.4
"This retrospective study on early and locally advanced esophageal cancer was conducted to evaluate locoregional failure and its impact on survival by comparing involved field radiotherapy (IFRT) with elective nodal irradiation (ENI) in combination with concurrent chemotherapy."	( Involved-field radiotherapy (IFRT) versus elective nodal irradiation (ENI) in combination with concurrent chemotherapy for 239 esophageal cancers: a single institutional retrospective study. Imae, T; Nakagawa, K; Ohtomo, K; Okuma, K; Omori, M; Takenaka, R; Yamashita, H, 2015)	0.42
"This Phase II trial was designed to evaluate the efficacy and safety of docetaxel combined with nedaplatin as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma."	( Phase II trial of docetaxel combined with nedaplatin for patients with recurrent and metastatic nasopharyngeal carcinoma. Cheng, ZB; Liao, H; Lin, Z; Liu, YM; Lv, BJ; Peng, PJ; Tang, C; Wang, SY; Wang, ZH, 2015)	0.42
"Docetaxel combined with nedaplatin offers a satisfactory clinical activity and an acceptable safety profile as first-line chemotherapy for patients with recurrent and metastatic nasopharyngeal carcinoma."	( Phase II trial of docetaxel combined with nedaplatin for patients with recurrent and metastatic nasopharyngeal carcinoma. Cheng, ZB; Liao, H; Lin, Z; Liu, YM; Lv, BJ; Peng, PJ; Tang, C; Wang, SY; Wang, ZH, 2015)	0.42
"To study the efficacy of bevacizumab combined with nedaplatin in the treatment of ovarian cancer and its effects on tumor markers and immunity of patients."	( Efficacy of bevacizumab combined with nedaplatin in the treatment of ovarian cancer and its effects on tumor markers and immunity of patients. Chen, C; Fan, T; Li, X; Wang, S; Zhang, H, )	0.13
" Patients in the control group were treated with carboplatin alone, while those in the experimental group were treated with bevacizumab combined with nedaplatin, based on the treatment in the control group."	( Efficacy of bevacizumab combined with nedaplatin in the treatment of ovarian cancer and its effects on tumor markers and immunity of patients. Chen, C; Fan, T; Li, X; Wang, S; Zhang, H, )	0.13
"Bevacizumab combined with nedaplatin has good efficacy in the treatment of ovarian cancer, which can significantly improve the tumor markers, enhance the immunity and ameliorate the QoL of patients, with fewer adverse reactions, so it is worthy of popularization and application."	( Efficacy of bevacizumab combined with nedaplatin in the treatment of ovarian cancer and its effects on tumor markers and immunity of patients. Chen, C; Fan, T; Li, X; Wang, S; Zhang, H, )	0.13
"To investigate the efficacy and safety of irinotecan combined with nedaplatin in the treatment of small cell lung cancer (SCLC)."	( The efficacy and safety of irinotecan combined with nedaplatin in the treatment of small cell lung cancer. Fang, S; Fu, J; Wang, D; Wang, Y; Wen, Y; Yin, X, )	0.13
" Thirty-two patients in group A were treated with irinotecan combined with nedaplatin, while 32 patients in group B were treated with irinotecan combined with cisplatin."	( The efficacy and safety of irinotecan combined with nedaplatin in the treatment of small cell lung cancer. Fang, S; Fu, J; Wang, D; Wang, Y; Wen, Y; Yin, X, )	0.13
"The efficacy of irinotecan combined with nedaplatin is good and the safety is high in the treatment of SCLC and it can be used as a clinical treatment method of SCLC and is worthy of being generalized."	( The efficacy and safety of irinotecan combined with nedaplatin in the treatment of small cell lung cancer. Fang, S; Fu, J; Wang, D; Wang, Y; Wen, Y; Yin, X, )	0.13
"To explore the efficacy of nedaplatin combined with docetaxel in patients with nasopharyngeal carcinoma and its influence on the expressions of esophageal cancer-related gene 4 (ECRG4) and vascular endothelial growth factor (VEGF)."	( Efficacy of nedaplatin combined with docetaxel in patients with nasopharyngeal carcinoma and its influence on ECRG4 and VEGF expressions. Deng, M; Gao, Y; Liu, G; Zuo, D, )	0.13
" Chemotherapy combining cisplatin with fluorouracil was administered in the control group, while nedaplatin combined with docetaxel was given in the observation group."	( Efficacy of nedaplatin combined with docetaxel in patients with nasopharyngeal carcinoma and its influence on ECRG4 and VEGF expressions. Deng, M; Gao, Y; Liu, G; Zuo, D, )	0.13
"Nedaplatin combined with docetaxel has better short-term efficacy in nasopharyngeal carcinoma, with milder adverse reactions, and it can reduce the levels of serum HIF-1α and VEGF, and up-regulate ECRG4 expression in patients, exerting an anti-carcinoma effect."	( Efficacy of nedaplatin combined with docetaxel in patients with nasopharyngeal carcinoma and its influence on ECRG4 and VEGF expressions. Deng, M; Gao, Y; Liu, G; Zuo, D, )	0.13
"To investigate the therapeutic effect of Elemene combined with Nedaplatin (ECN) on malignant pleural effusion (MPE) and its adverse reactions."	( Effects of intracavitary administration of elemene combined with nedaplatin on malignant pleural effusion. Chen, KH; Chen, R; Ning, Z; Ou, XM; Yang, YS; Yu, HY; Zhang, CY, 2022)	0.72
"A case-control study was adopted to investigate the efficacy and side effects of irinotecan combined with nedaplatin (NP) versus paclitaxel combined with cisplatin for locally advanced cervical cancer (CC) neoadjuvant chemotherapy (NACT) and to analyze the changes in tumor marker levels."	( Efficacy and Side Effects of Irinotecan Combined with Nedaplatin versus Paclitaxel Combined with Cisplatin in Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer and Tumor Marker Analysis: Based on a Retrospective Analysis. Chen, Z; Jiang, Y; Song, B, 2022)	0.72
" Among them, 53 patients received paclitaxel combined with cisplatin as the control group, and the other 43 patients received irinotecan combined with NP as the observation group."	( Efficacy and Side Effects of Irinotecan Combined with Nedaplatin versus Paclitaxel Combined with Cisplatin in Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer and Tumor Marker Analysis: Based on a Retrospective Analysis. Chen, Z; Jiang, Y; Song, B, 2022)	0.72
"Irinotecan in combination with nedaplatin can be an effective neoadjuvant chemotherapy regimen for advanced localized cervical cancer, particularly in patients with combined diabetes."	( Efficacy and Side Effects of Irinotecan Combined with Nedaplatin versus Paclitaxel Combined with Cisplatin in Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer and Tumor Marker Analysis: Based on a Retrospective Analysis. Chen, Z; Jiang, Y; Song, B, 2022)	0.72
"Patients with locally advanced lung SCC (stage IIIA, IIIB) who received PD-1 inhibitor combined with nab-PTX and NED between February 2019 and June 2021 in Weihai Municipal Hospital were included and underwent surgical treatment 4 weeks after 2-4 cycles neoadjuvant therapy."	( Efficacy and Safety of the PD-1 Inhibitor Combined with Albumin-Bound Paclitaxel and Nedaplatin in Preoperative Neoadjuvant Therapy of Unresectable Stage III Lung Squamous Cell Carcinoma. Li, L; Song, C; Sun, Z; Wang, W; Xu, H; Yin, J, 2022)	0.72
"The neoadjuvant therapy of the PD-1 inhibitor combined with nab-PTX and NED demonstrated remarkable therapeutic efficacy and good safety on stage III lung SCC without increasing the risk of TRAE, mortality and surgery-related complications, or impede surgery feasibility."	( Efficacy and Safety of the PD-1 Inhibitor Combined with Albumin-Bound Paclitaxel and Nedaplatin in Preoperative Neoadjuvant Therapy of Unresectable Stage III Lung Squamous Cell Carcinoma. Li, L; Song, C; Sun, Z; Wang, W; Xu, H; Yin, J, 2022)	0.72

Excerpt	Reference	Relevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" These results showed that 254-S was well absorbed into systemic circulation from abdominal ascites as an active form."	( [Pharmacokinetics of cis-diammine (glycolato) platinum (254-S), a new platinum antitumor agent, following an intravenous and intraperitoneal infusion bioactive platinum concentration profile]. Hirabayashi, K; Oguma, T; Okada, E; Shimamura, K, 1990)	0.28

Excerpt	Relevance	Reference
" Increases in exposure time of K562 cells to DWA2114R resulted in progressive shifting of the dose-response curve to the left, or more effective cell growth inhibition of the cells."	( Antitumor activities of new platinum compounds, DWA2114R, NK121 and 254-S, against human leukemia cells sensitive or resistant to cisplatin. Kobayashi, H; Miyachi, H; Ogawa, T; Takemura, Y, 1991)	0.28
" In addition, the toxicities of the combination therapies were lower than what was produced by the highest dosage of CDDP (4 mg/kg/day for 5 days)."	( Advantages in combination chemotherapy using cisplatin and its analogues for human testicular tumor xenografts. Hida, S; Okada, K; Yoshida, O, 1990)	0.28
" The overall in vitro response rate (defined as less than 50% survival of tumor colony forming units) for 254-S was observed in 10/29 and 20/30 evaluable specimens isolated freshly from NSCLC patients with continuous exposure at 1 and 10 micrograms/ml, respectively, indicating a positive dose-response relationship."	( Antitumor activity of a new platinum compound (glycolate-o,o') diammineplatinum (II) (254-S), against non-small cell lung carcinoma grown in a human tumor clonogenic assay system. Kanzawa, F; Matsushima, Y; Nakagawa, K; Nakano, H; Saijo, N; Sasaki, Y; Takahashi, H, )	0.13
"A preliminary co-operative study by 7 institutes was conducted to determine the optimal dosage of the combination regimen with nedaplatin, bleomycin and ifosfamide, which is used in a phase III clinical study, to investigate its efficacy as neoadjuvant chemotherapy against advanced cervical cancer of the uterus."	( [Combination chemotherapy with nedaplatin, bleomycin and ifosfamide for advanced cervical cancer of the uterus--a preliminary study for phase III clinical study]. Hatae, M; Hirabayashi, K; Kanazawa, K; Noda, K; Ozaki, M; Terashima, Y; Yakushiji, M, 1997)	0.3
" Combined dosing of NDP with GEM resulted in synergistically enhanced inhibition of tumor growth in the Ma44 tumor model."	( Preclinical in vivo antitumor efficacy of nedaplatin with gemcitabine against human lung cancer. Hojo, K; Maekawa, R; Maki, H; Matsumoto, M; Nishitani, Y; Takeda, Y; Wada, T; Yoshioka, T, 2001)	0.31
"The pharmacodynamic effects of cis-diammine(glycolato)platinum (nedaplatin, 254-S) in vitro have been reported, but the dosage and exposure time in vitro have not always been based on clinical observations of the drug's actions in vivo."	( Cytocidal effect and DNA damage of nedaplatin in vitro by simulating pharmacokinetic parameters. Hongo, A; Kawanishi, K; Kodama, J; Kudo, T; Miyagi, Y; Nakamura, K; Yamamoto, J; Yoshinouchi, M, 2001)	0.31
" In contrast, the sequential dosing of TXL prior to NDP (TN therapy) resulted in synergistically enhanced inhibition of tumor growth with less toxicity compared with the NT therapy."	( Sequence-dependent antitumor efficacy of combination chemotherapy with nedaplatin, a newly developed platinum, and paclitaxel. Maekawa, R; Uchida, N; Yamada, H; Yoshioka, T, 2001)	0.31
" The combined dosing of NDP with GEM resulted in synergistically enhanced inhibition of tumor growth against Ma44/GEM."	( Preclinical combination chemotherapy of nedaplatin with gemcitabine against gemcitabine-refractory human lung cancer. Hojo, K; Maekawa, R; Matsumoto, M; Nishitani, Y; Takeda, Y; Wada, T; Yoshioka, T, 2002)	0.31
"To predict the optimal dosage for nedaplatin ( cis-diammineglycolatoplatinum), an anticancer drug and a platinum derivative like cisplatin and carboplatin, a simple formula was developed based on renal function in Japanese adult cancer patients."	( A formula for predicting optimal dosage of nedaplatin based on renal function in adult cancer patients. Ishibashi, T; Oguma, T; Yano, Y, 2002)	0.31
" Further study of dosage and schedule is necessary, however, CDGP/5-FU combined with radiation therapy could be used as choices of chemoradiotherapy for esophageal cancer in the future."	( [Clinical study of the combination of small amount of nedaplatin (CDGP)/5-FU with radiation for the treatment of esophageal cancer]. Endo, T; Hara, T; Hoshikawa, Y; Iino, S; Inaba, H; Kato, N; Kitajima, S; Kobayashi, Y; Koitabashi, Y; Miyazaki, A; Nakagawa, T; Nakaya, S; Ogihara, K; Tsuda, T; Watanabe, Y, 2002)	0.31
" These population pharmacokinetic estimates are useful for setting initial dosing of nedaplatin using its population mean and can also be used for setting appropriate dosage regimens using empirical Bayesian forecasting."	( Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients. Ishibashi, T; Oguma, T; Yano, Y, 2003)	0.32
" We compared the expected AUC (area under the curve) with the actual AUC in primary oral cancer cases to assess the optimal dosage of CDGP for intra-arterial chemotherapy and to study relevance of AUC, effectiveness of independent chemotherapy and side effects."	( [Clinical study of the area under the blood concentration-time curve of targeting intra-arterial infusion chemotherapy with nedaplatin for primary oral cancer]. Iwasaki, A; Miyake, M; Nagahata, S; Ogawa, T; Ohbayashi, Y; Ohkawa, M; Toyama, Y, 2004)	0.32
"Area under the curve (AUC) is a very important parameter for determination of optimal dosage of antineoplastic agents in order to avoid side effects and achieve high effectiveness."	( [Clinical study for determination of the dosage formula for intra-arterial infusion chemotherapy with nedaplatin]. Iwasaki, A; Miyake, M; Nagahata, S; Ogawa, T; Ohbayashi, Y; Ohkawa, M; Toyama, Y, 2004)	0.32
" Total Pt concentration in tongue tissue was measured on the dosage and nondosage side."	( [Pharmacodynamics of tongue tissue and plasma after intraarterial infusion of cis-diammine glycolato platinum (CDGP)]. Kano, M; Matsui, T, 2004)	0.32
" The results of linear regression analysis suggested that the relative reduction ratio of PLT significantly correlated with AUC after nedaplatin administration and the relationship was not affected by the dosing course of nedaplatin nor the combination of other cancer drugs."	( Determination of optimal dosage for nedaplatin based on pharmacokinetic and toxicodynamic analysis. Ishibashi, T; Oguma, T; Yano, Y, )	0.13
"The aim of this study was to determine the optimal sampling design for empirical Bayesian forecasting for nedaplatin, and also to develop a simple formula for estimating the area under the plasma concentration-time curve (AUC) of platinum which relates to hematological toxicity after nedaplatin dosing using limited sampling points."	( Optimal sampling and limited sampling strategies for estimation of unbound platinum AUC after nedaplatin infusion. Fukumura, K; Ishibashi, T; Oguma, T; Yano, Y, )	0.13
" The dosage of each drug was based on that for a patient undergoing hemodialysis, and the plasma concentration of each drug was examined."	( [Chemotherapy for an esophageal cancer patient undergoing continuous ambulatory peritoneal dialysis for chronic renal failure and measurement of plasma concentration of the drug]. Maruyama, K; Motoyama, S; Ogawa, J; Ohta, H; Okuyama, M; Oyake, J; Tsuchiya, N, 2005)	0.33
"The aim of this study was to determine the pharmacokinetics of low-dose nedaplatin combined with paclitaxel and radiation therapy in patients having non-small-cell lung carcinoma and establish the optimal dosage regimen for low-dose nedaplatin."	( Pharmacokinetics of low-dose nedaplatin and validation of AUC prediction in patients with non-small-cell lung carcinoma. Niioka, T; Shimizu, M; Sugawara, K; Takahata, T; Tateishi, T; Uno, T; Yasui-Furukori, N, 2007)	0.34
"The dosage regimen of low-dose nedaplatin should be established based on Ccr rather than on BSA."	( Pharmacokinetics of low-dose nedaplatin and validation of AUC prediction in patients with non-small-cell lung carcinoma. Niioka, T; Shimizu, M; Sugawara, K; Takahata, T; Tateishi, T; Uno, T; Yasui-Furukori, N, 2007)	0.34
" The dosage of chemotherapy was as follows: DOC 60 mg/m(2) on day 1 by infusion over 2 hours; CDGP 20-30 mg/m(2)/day on day 1 to 5 by infusion over 1 hour, and 5-FU 600 mg/m(2)/day on day 1 to 5 by 5 days continuous infusion."	( [Phase I/II clinical trial of induction chemotherapy with nedaplatin (CDGP), docetaxel (DOC) and 5-fluorouracil (5-FU) for squamous cell carcinoma of head and neck]. Iwabuchi, H; Nakayama, S; Uchiyama, K, 2007)	0.34
"Despite evidence in the literature suggesting that a strong correlation exists between the pharmacokinetic parameters and pharmacodynamic effect of anticancer agents, many of these agents are still dosed by body surface area."	( A systematic review of limited sampling strategies for platinum agents used in cancer chemotherapy. Ensom, MH; Loh, GW; Ting, LS, 2007)	0.34
" The current results suggest that NDP has the potential risk to cause nephrotoxicity at a human therapeutic dose without hydration and that pre- and post-hydration at dosing can ameliorate this nephrotoxicity."	( Time course of the change and amelioration of nedaplatin-induced nephrotoxicity in rats. Maruyama, T; Masuda, A; Nakamura, M; Torii, M; Tsuchiya, N; Uehara, T; Yamate, J, 2008)	0.35
" This study aimed to determine the recommended dosage of nedaplatin plus ifosfamide chemoradiotherapy for advanced squamous cell carcinoma (SCC) of the uterine cervix."	( Phase I study of chemoradiation with nedaplatin and ifosfamide in patients with advanced squamous cell carcinoma of the uterine cervix. Hiramatsu, Y; Hongo, A; Kanazawa, S; Kodama, J; Moriya, S; Nakamura, K; Seki, N; Takemoto, M, )	0.13
" In the standard dosage regimen for cervical carcinoma, CDGP is administered once every four weeks (monthly regimen)."	( Initial analysis of relationship between plasma platinum concentration and hematological adverse reaction associated with weekly chemotherapy using nedaplatin in combination with radiotherapy for cervical carcinoma. Hamada, Y; Hayakawa, K; Kotani, A; Kusu, F; Naitoh, H; Niibe, Y; Takayanagi, R; Tsunoda, S; Unno, N; Yago, K; Yamada, Y, 2010)	0.36
" The optimal dosing for CBDCA is determined by the area under the curve (AUC) using Calvert's formula."	( Evaluation of a formula for individual dosage of nedaplatin based on renal function. Fujiwara, H; Itamochi, H; Kigawa, J; Machida, S; Oishi, T; Sato, S; Shimada, M; Suzuki, M; Takei, Y, 2012)	0.38
" We conducted a phase I study to determine the AUC-calculated optimal dosage of NDP used in combination chemotherapy with irinotecan (CPT-11) for gynecologic malignancies."	( Area under the curve calculation of nedaplatin dose used in combination chemotherapy with irinotecan in a phase I study of gynecologic malignancies. Fujiwara, H; Harada, T; Itamochi, H; Kigawa, J; Machida, S; Oishi, T; Sato, S; Shimada, M; Suzuki, M; Takei, Y, 2012)	0.38
"The recommended dosage of NDP calculated by AUC with Ishibashi's formula was set to AUC 10 in combination chemotherapy with CPT-11."	( Area under the curve calculation of nedaplatin dose used in combination chemotherapy with irinotecan in a phase I study of gynecologic malignancies. Fujiwara, H; Harada, T; Itamochi, H; Kigawa, J; Machida, S; Oishi, T; Sato, S; Shimada, M; Suzuki, M; Takei, Y, 2012)	0.38

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
phosphopantetheinyl transferase	Bacillus subtilis	Potency	7.9433	0.1413	37.9142	100.0000	AID1490
EWS/FLI fusion protein	Homo sapiens (human)	Potency	5.8992	0.0013	10.1577	42.8575	AID1259256
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	8.9125	0.0355	20.9770	89.1251	AID504332
peripheral myelin protein 22	Rattus norvegicus (Norway rat)	Potency	36.1254	0.0056	12.3677	36.1254	AID624032
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Assay ID	Title	Year	Journal	Article
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	12 (2.21)	18.7374
1990's	71 (13.10)	18.2507
2000's	188 (34.69)	29.6817
2010's	234 (43.17)	24.3611
2020's	37 (6.83)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Trials	148 (25.74%)	5.53%
Reviews	0 (0.00%)	6.00%
Reviews	29 (5.04%)	6.00%
Case Studies	0 (0.00%)	4.05%
Case Studies	99 (17.22%)	4.05%
Observational	0 (0.00%)	0.25%
Observational	3 (0.52%)	0.25%
Other	8 (100.00%)	84.16%
Other	296 (51.48%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (44)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Phase I Study of S-1 Plus Nedaplatin With Concurrent Radiotherapy for Advanced Esophageal Cancer [NCT01175460]	Phase 1	15 participants (Actual)	Interventional	2010-01-31	Completed
A Randomized, Two Arm Study to Investigate Bronchial Arterrial Infusing (BAI) Plus Three-dimensional Conformal Radiotherapy (3DCRT) in Local Advanced Non-small Cell Lung Cancer (NSCLC) [NCT01201044]		80 participants (Anticipated)	Interventional	2010-01-31	Recruiting
SHR-1210, a Novel Anti-PD-1 Antibody, in Combination With Apatinib and Irinotecan/Paclitaxel Liposome Plus Nedaplatin in Patients With Previously Untreated Advanced or Metastatic Esophageal Squamous Cell Cancer: a Phase II Study [NCT03603756]	Phase 2	45 participants (Anticipated)	Interventional	2018-07-31	Recruiting
An Open-label, Randomized Clinical Trial of Recombinant Human Endostatin (Endo) Combined With Chemotherapy Compared With Chemotherapy for Adjuvant Treatment of Esophageal Cancer [NCT03649945]	Phase 2	186 participants (Anticipated)	Interventional	2018-11-30	Not yet recruiting
Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in Induction Chemotherapy Plus Concurrent Chemoradiotherapy for Locoregionally Advanced NPC： a Phase 3, Multicentre, Non-inferiority, Randomised Factorial Trial [NCT03503136]	Phase 3	632 participants (Anticipated)	Interventional	2018-06-30	Not yet recruiting
A Randomized Phase III Study of Concurrent Weekly Nedaplatin or Cisplatin With IMRT in NPC Patients [NCT02301208]	Phase 3	120 participants (Anticipated)	Interventional	2014-12-31	Not yet recruiting
EFFECT-neo: A Prospective, Open-label, Multicenter Phase III Study to Evaluate Efficacy and Safety of Pembrolizumab Combined With Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC [NCT06102395]	Phase 3	272 participants (Anticipated)	Interventional	2023-05-01	Recruiting
Phase II Study to Evaluate Efficacy and Safety of Intensity-modulated Radiation Therapy Combined With Cisplatin or Nedaplatin Chemotherapy in Patients With Nasopharyngeal Carcinoma [NCT01265147]	Phase 2	20 participants (Anticipated)	Interventional	2011-01-31	Not yet recruiting
The Effect of Celecoxib on Concurrent Chemoradiation With Weekly Nedaplatin in Nasopharyngeal Carcinoma [NCT02537925]	Phase 3	120 participants (Anticipated)	Interventional	2014-01-31	Recruiting
Phase II Study of Liposomal Paclitaxel With Nedaplatin as First-line in Advanced or Recurrent Esophageal Carcinoma [NCT02861690]	Phase 2	72 participants (Actual)	Interventional	2010-01-31	Completed
Prospective, Multicentric, Randomized Clinical Study of Radiotherapy Combined With Nedaplatin Contrast and Cisplatin for the Treatment of Locally Advanced Head and Neck Squamous Carcinoma [NCT05039606]	Phase 2	164 participants (Anticipated)	Interventional	2021-09-30	Not yet recruiting
Nedaplatin (Jiebaishu®) and Docetaxel in Comparison With Cisplatin and Docetaxel Regimen for the First Line Treatment of Advanced Squamous Cell Carcinoma of Lung(IIIB/IV): Randomized, Controlled, Multicentre Study [NCT02088515]	Phase 4	290 participants (Actual)	Interventional	2013-12-31	Completed
Fruquintinib Combined With Camrelizumab, Paclitaxel Liposome and Nedaplatin as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma [NCT06010212]	Phase 1/Phase 2	36 participants (Anticipated)	Interventional	2023-08-25	Not yet recruiting
A Randomized, Open Label, Single Centre Clinical Trial of Pelvic External Radiotherapy Combined With 252-Cf Neutron Intracavitary Brachytherapy With or Without Platinum in Treatment of Local Advanced Cervical Cancer [NCT02835404]	Phase 2	200 participants (Anticipated)	Interventional	2012-11-30	Recruiting
Nedaplatin Versus Cisplatin in Induction Chemotherapy Combined With Concurrent Chemoradiotherapy for Locally Advanced Nasopharyngeal Carcinoma：a Prospective, Parallel, Randomized, Open Labeled, Phase III Non-Inferiority Clinical Study [NCT04437329]	Phase 3	352 participants (Anticipated)	Interventional	2020-08-01	Recruiting
[NCT02789189]	Phase 2	60 participants (Anticipated)	Interventional	2016-06-30	Terminated
Clinical Application of Efficacy Prediction Model Based on Epigenomics Sequencing Technology in Neoadjuvant Immunotherapy for Esophageal Cancer [NCT05880082]	Phase 2	62 participants (Anticipated)	Interventional	2023-05-31	Not yet recruiting
Nedaplatin/Docetaxel Versus Cisplatin/Docetaxel in Treatment of Advanced/Relapsed Squamous Cell Lung Cancer :A Randomized, Open, Parallel, Multicentre, Phase Ⅲ Study [NCT02643407]	Phase 3	488 participants (Anticipated)	Interventional	2015-10-31	Recruiting
Advanced Non-small Cell Lung Cancer With Chinese Medicine Comprehensive Treatment Plan [NCT02777788]	Phase 2/Phase 3	120 participants (Anticipated)	Interventional	2014-09-30	Active, not recruiting
Induction Chemotherapy With Nedaplatin, Docetaxel and 5-Fluorouracil Followed by Concurrent Nedaplatin and Radiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: a Single Arm, Open Label, Multicenter, Phase II Clinical Study. [NCT04834206]	Phase 2	32 participants (Actual)	Interventional	2021-05-01	Completed
Nedaplatin or Cisplatin Combined With Pemetrexed in the First Line Treatment of Advanced Adenocarcinoma：A Prospective Multi-center Phase III Randomized Controlled Trial [NCT02607592]	Phase 3	293 participants (Anticipated)	Interventional	2015-08-31	Recruiting
A Prospective Observational Study of the Efficacy and Safety of CPT-11 Plus Platinum Analogues Regimens for UGT1A1 Genotype Guided Patients With Several Solid Tumors [NCT01040312]		321 participants (Actual)	Observational	2009-10-15	Completed
A Phase II Study of Daily Low-Dose of Nedaplatin (CDGP:Cis-Diammine-Glycolatoplatinum) and Continuous Infusion of 5-FU Combined With Radiation for the Treatment of Esophageal Cancer [NCT00197444]	Phase 2	33 participants (Actual)	Interventional	2003-01-31	Completed
A Single-arm，Single Center，Prospective，Phase II Clinical Study of Camrelizumab Combined With Concurrent Chemoradiotherapy for Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma [NCT06170697]	Phase 2	46 participants (Anticipated)	Interventional	2023-03-01	Recruiting
Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Locally Advanced Esophageal Carcinoma [NCT05777707]	Phase 1/Phase 2	89 participants (Anticipated)	Interventional	2020-10-29	Recruiting
Prospective, Non-randomised Phase Ⅱ Study of Simultaneous Integrated Boost Radiotherapy and Concurrent Nimotuzumab or Chemotherapy for Locally Advanced Esophageal Carcinoma [NCT02858206]	Phase 2	120 participants (Anticipated)	Interventional	2016-06-30	Recruiting
A Multi-institutional, Randomized Controlled, Phase II Clinical Trial on Comparison of Efficacy and Safety of Nedaplatin Plus 5-Fu Combined With and Without Endostar® Continuous Intravenous Infusion in Refractory Nasopharyngeal Carcinoma [NCT02590133]	Phase 2	328 participants (Anticipated)	Interventional	2015-07-31	Recruiting
Efficacy and Safety ofToripalimab Combined With AP-induced Chemotherapyfollowed by Concurrent Chemoradiotherapy and Toripalimab-maintenance Therapysequentially in Patients With Non-metastatic IVB Hypopharyngeal Cancer : Aopen-lablc, Single-arm ,Phase II C [NCT05860335]	Phase 2	30 participants (Anticipated)	Interventional	2023-05-31	Not yet recruiting
A Multicenter Trial Evaluating the Efficacy and Safety of Nedaplatin Plus Docetaxel in Neoadjuvant Chemotherapy Followed by Nedaplatin in Concurrent Chemoradiation for Patients With Locoregionally Advanced Nasopharyngeal Carcinoma [NCT01479504]	Phase 3	2 participants (Anticipated)	Interventional	2011-11-30	Recruiting
A Prospective Single-arm Phase Ⅱ Study of Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma [NCT04844385]	Phase 2	83 participants (Anticipated)	Interventional	2021-02-20	Recruiting
A Prospective, Open-label, Phase I Study of Docetaxel and Nedaplatin Twice Weekly in Combination With Chest Radiotherapy in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma [NCT02964455]	Phase 1	12 participants (Actual)	Interventional	2016-11-30	Completed
A Randomized Phase III Non-inferiority Study of Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma [NCT01540136]	Phase 3	402 participants (Actual)	Interventional	2012-02-29	Completed
A Phase II/III Study of Adjuvant Chemoradiotherapy, Radiotherapy After Surgery Versus Surgery Alone in Patients With Stage ⅡB-Ⅲ Esophageal Carcinoma [NCT02279134]	Phase 2/Phase 3	360 participants (Anticipated)	Interventional	2014-10-31	Active, not recruiting
A Single Center, Non-randomized, Open Phase II Clinical Study of Albumin-bound Paclitaxel Plus Nedaplatin in Patients With Advanced, Recurrent Metastatic Cervical Cancer [NCT01667211]	Phase 2	30 participants (Anticipated)	Interventional	2011-11-30	Recruiting
Adjuvant Chemotherapy or Not for NPC Patients Staged N2-3M0 After Concurrent Chemotherapy :a Phase Ⅱ Study [NCT01694576]	Phase 2	10 participants (Actual)	Interventional	2012-09-30	Terminated(stopped due to slow patient enrollment)
IMRT With Concurrent Chemotherapy and Cetuximab Against Locoregionally Advanced NPC: a Phase 1 Study [NCT01712919]	Phase 1/Phase 2	61 participants (Actual)	Interventional	2010-05-31	Completed
Phase Ⅱ Trial of Temozolomide Plus Concurrent Whole-Brain Radiation Followed by TNV Regimen as Adjuvant Therapy for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma (PCNSL) [NCT01735747]	Phase 2	16 participants (Anticipated)	Interventional	2008-06-30	Active, not recruiting
Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma [NCT05515315]	Phase 2	93 participants (Anticipated)	Interventional	2022-10-09	Not yet recruiting
Sintilimab Plus Bevacizumab and Platinum-Based Doublet Chemotherapy as First-Line Treatment for Advanced Non-squamous Non-Small-Cell Lung Cancer With Negative Driver Gene: a Single-center, Single-Arm Trial [NCT05648071]	Phase 3	60 participants (Anticipated)	Interventional	2021-12-01	Recruiting
A Phase II Trial of Recombinant Human Endostatin Injection (Endostar) Combined With Paclitaxel and Nedaplatin as First-line Therapy in Treating Patients With Recurrent or Metastatic Esophageal Cancer [NCT02350517]	Phase 2	52 participants (Actual)	Interventional	2015-01-31	Completed
Nimotuzumab Combined With Neoadjuvant Chemotherapy (TPF) in the Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma [NCT05351762]	Phase 2	55 participants (Anticipated)	Interventional	2022-07-01	Not yet recruiting
The Phase II Trial of SHR-1210 Combined With Preoperative Chemotherapy or Apatinib for Locally Advanced Esophageal Squamous Cell Carcinoma [NCT03917966]	Phase 2	80 participants (Anticipated)	Interventional	2020-04-07	Recruiting
A Prospective Study on the Safety and Effectiveness of Toripalimab Combined With Neoadjuvant Radiotherapy and Chemotherapy in the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma [NCT04888403]	Phase 2	45 participants (Anticipated)	Interventional	2021-12-31	Not yet recruiting
A Phase Ⅰ/Ⅱ Study of Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy in Patients With Locally Advanced Esophageal Carcinoma [NCT02429622]	Phase 1/Phase 2	80 participants (Actual)	Interventional	2015-01-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
adenine [no description available]	2.49	2	0	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
uracil 2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder	2.42	2	0	pyrimidine nucleobase; pyrimidone	allergen; Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; prodrug; Saccharomyces cerevisiae metabolite
p-aminohippuric acid p-Aminohippuric Acid: The glycine amide of 4-aminobenzoic acid. Its sodium salt is used as a diagnostic aid to measure effective renal plasma flow (ERPF) and excretory capacity.. p-aminohippurate : A hippurate that is the conjugate base of p-aminohippuric acid, arising from deprotonation of the carboxy group.. p-aminohippuric acid : An N-acylglycine that is the 4-amino derivative of hippuric acid; used as a diagnostic agent in the measurement of renal plasma flow.	1.97	1	0	N-acylglycine	Daphnia magna metabolite
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	16.61	151	41	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
ifosfamide [no description available]	7.16	20	5	ifosfamides	alkylating agent; antineoplastic agent; environmental contaminant; immunosuppressive agent; xenobiotic
metoclopramide Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.. metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.	2.02	1	0	benzamides; monochlorobenzenes; substituted aniline; tertiary amino compound	antiemetic; dopaminergic antagonist; environmental contaminant; gastrointestinal drug; xenobiotic
oxonic acid Oxonic Acid: Antagonist of urate oxidase.	9.97	28	8	1,3,5-triazines; monocarboxylic acid
tegafur [no description available]	15.07	31	8	organohalogen compound; pyrimidines
mitomycin Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.. mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.	9.3	3	0	mitomycin	alkylating agent; antineoplastic agent
floxuridine Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.. floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.	2.07	1	0	nucleoside analogue; organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; radiosensitizing agent
cytarabine [no description available]	2.01	1	0	beta-D-arabinoside; monosaccharide derivative; pyrimidine nucleoside	antimetabolite; antineoplastic agent; antiviral agent; immunosuppressive agent
xanthenes Xanthenes: Compounds with three aromatic rings in linear arrangement with an OXYGEN in the center ring.	2.08	1	0	xanthene
thiophenes Thiophenes: A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur.. thiophenes : Compounds containing at least one thiophene ring.	3.64	1	1	mancude organic heteromonocyclic parent; monocyclic heteroarene; thiophenes; volatile organic compound	non-polar solvent
quinazolines Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.	4.45	2	2	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
thiazoles [no description available]	2	1	0	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
elemene elemene: a sclerosing and antineoplastic agent isolated from Curcuma wenyujin & Rhizoma zedoariae; beta- and delta- elemene are also available	7.41	1	0
resazurin resazurin: used as indicator in detection of hyposulfite (sulfoxylate); in food research (reductase test); structure	2.08	1	0	phenoxazine
3-hydroxyflavone 3-hydroxyflavone: structure given in first source. flavonol : A monohydroxyflavone that is the 3-hydroxy derivative of flavone.	2.11	1	0	flavonols; monohydroxyflavone
deoxycytidine [no description available]	12.54	37	10	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
d-alpha tocopherol Vitamin E: A generic descriptor for all TOCOPHEROLS and TOCOTRIENOLS that exhibit ALPHA-TOCOPHEROL activity. By virtue of the phenolic hydrogen on the 2H-1-benzopyran-6-ol nucleus, these compounds exhibit varying degree of antioxidant activity, depending on the site and number of methyl groups and the type of ISOPRENOIDS.. tocopherol : A collective name for a group of closely related lipids that contain a chroman-6-ol nucleus substituted at position 2 by a methyl group and by a saturated hydrocarbon chain consisting of three isoprenoid units. They are designated as alpha-, beta-, gamma-, and delta-tocopherol depending on the number and position of additional methyl substituents on the aromatic ring. Tocopherols occur in vegetable oils and vegetable oil products, almost exclusively with R,R,R configuration. Tocotrienols differ from tocopherols only in having three double bonds in the hydrocarbon chain.. vitamin E : Any member of a group of fat-soluble chromanols that exhibit biological activity against vitamin E deficiency. The vitamers in this class consists of a chroman-6-ol core which is substituted at position 2 by a methyl group and (also at position 2) either a saturated or a triply-unsaturated hydrocarbon chain consisting of three isoprenoid units. The major function of vitamin E is to act as a natural antioxidant by scavenging free radicals and molecular oxygen.. (R,R,R)-alpha-tocopherol : An alpha-tocopherol that has R,R,R configuration. The naturally occurring stereoisomer of alpha-tocopherol, it is found particularly in sunflower and olive oils.	2.6	1	0	alpha-tocopherol	algal metabolite; antiatherogenic agent; anticoagulant; antioxidant; antiviral agent; EC 2.7.11.13 (protein kinase C) inhibitor; immunomodulator; micronutrient; nutraceutical; plant metabolite
doxifluridine doxifluridine : A pyrimidine 5'-deoxyribonucleoside that is 5-fluorouridine in which the hydroxy group at the 5' position is replaced by a hydrogen. It is an oral prodrug of the antineoplastic agent 5-fluorouracil. Designed to circumvent the rapid degradation of 5-fluorouracil by dihydropyrimidine dehydrogenase in the gut wall, it is converted into 5-fluorouracil in the presence of pyrimidine nucleoside phosphorylase.	2.07	1	0	organofluorine compound; pyrimidine 5'-deoxyribonucleoside	antimetabolite; antineoplastic agent; prodrug
megestrol Megestrol: A progestational hormone used most commonly as the acetate ester. As the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor. It has also been used in the palliative treatment of breast cancer.. megestrol : A 3-oxo Delta(4)-steroid that is pregna-4,6-diene-3,20-dione substituted by a methyl group at position 6 and a hydroxy group at position 17.	8.45	1	1	17alpha-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(4) steroid; tertiary alpha-hydroxy ketone	antineoplastic agent; appetite enhancer; contraceptive drug; progestin; synthetic oral contraceptive
buthionine sulfoximine Buthionine Sulfoximine: A synthetic amino acid that depletes glutathione by irreversibly inhibiting gamma-glutamylcysteine synthetase. Inhibition of this enzyme is a critical step in glutathione biosynthesis. It has been shown to inhibit the proliferative response in human T-lymphocytes and inhibit macrophage activation. (J Biol Chem 1995;270(33):1945-7). 2-amino-4-(S-butylsulfonimidoyl)butanoic acid : A non-proteinogenic alpha-amino acid that is homocysteine in which the thiol group carries an oxo, imino and butyl groups.. S-butyl-DL-homocysteine (S,R)-sulfoximine : A sulfoximide that is the sulfoximine derivative of an analogue of DL-methionine in which the S-methyl group is replaced by S-butyl.	2.07	1	0	diastereoisomeric mixture; homocysteines; non-proteinogenic alpha-amino acid; sulfoximide	EC 6.3.2.2 (glutamate--cysteine ligase) inhibitor; ferroptosis inducer
platinum Platinum: A heavy, soft, whitish metal, resembling tin, with atomic number 78, atomic weight 195.084, symbol Pt. It is used in manufacturing equipment for laboratory and industrial use. It occurs as a black powder (platinum black) and as a spongy substance (spongy platinum) and may have been known in Pliny's time as alutiae.	5.48	15	1	elemental platinum; nickel group element atom; platinum group metal atom
camptothecin NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source	12.54	46	14	delta-lactone; pyranoindolizinoquinoline; quinoline alkaloid; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; genotoxin; plant metabolite
tetradecanoylphorbol acetate Tetradecanoylphorbol Acetate: A phorbol ester found in CROTON OIL with very effective tumor promoting activity. It stimulates the synthesis of both DNA and RNA.. phorbol ester : Esters of phorbol, originally found in croton oil (from Croton tiglium, of the family Euphorbiaceae). A number of phorbol esters possess activity as tumour promoters and activate the mechanisms associated with cell growth. Some of these are used in experiments as activators of protein kinase C.. phorbol 13-acetate 12-myristate : A phorbol ester that is phorbol in which the hydroxy groups at the cyclopropane ring juction (position 13) and the adjacent carbon (position 12) have been converted into the corresponding acetate and myristate esters. It is a major active constituent of the seed oil of Croton tiglium. It has been used as a tumour promoting agent for skin carcinogenesis in rodents and is associated with increased cell proliferation of malignant cells. However its function is controversial since a decrease in cell proliferation has also been observed in several cancer cell types.	1.98	1	0	acetate ester; diester; phorbol ester; tertiary alpha-hydroxy ketone; tetradecanoate ester	antineoplastic agent; apoptosis inducer; carcinogenic agent; mitogen; plant metabolite; protein kinase C agonist; reactive oxygen species generator
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	13.2	65	21	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
etoposide [no description available]	3.73	10	0	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
vindesine Vindesine: Vinblastine derivative with antineoplastic activity against CANCER. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS).	11.14	5	2	methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; primary carboxamide; tertiary alcohol; tertiary amino compound; vinca alkaloid	antineoplastic agent
epirubicin Epirubicin: An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.	7.44	2	0	aminoglycoside; anthracycline antibiotic; anthracycline; deoxy hexoside; monosaccharide derivative; p-quinones; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	antimicrobial agent; antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
topotecan Topotecan: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.. topotecan : A pyranoindolizinoquinoline used as an antineoplastic agent. It is a derivative of camptothecin and works by binding to the topoisomerase I-DNA complex and preventing religation of these 328 single strand breaks.	4.01	2	0	pyranoindolizinoquinoline	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor
gemcitabine gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.	12.03	34	9	organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; environmental contaminant; immunosuppressive agent; photosensitizing agent; prodrug; radiosensitizing agent; xenobiotic
irinotecan [no description available]	12.66	48	15	carbamate ester; delta-lactone; N-acylpiperidine; pyranoindolizinoquinoline; ring assembly; tertiary alcohol; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 5.99.1.2 (DNA topoisomerase) inhibitor; prodrug
capecitabine Capecitabine: A deoxycytidine derivative and fluorouracil PRODRUG that is used as an ANTINEOPLASTIC ANTIMETABOLITE in the treatment of COLON CANCER; BREAST CANCER and GASTRIC CANCER.. capecitabine : A carbamate ester that is cytidine in which the hydrogen at position 5 is replaced by fluorine and in which the amino group attached to position 4 is converted into its N-(penyloxy)carbonyl derivative. Capecitabine is a antineoplastic agent used in the treatment of cancers.	9.79	2	1	carbamate ester; cytidines; organofluorine compound	antimetabolite; antineoplastic agent; prodrug
iridium radioisotopes Iridium Radioisotopes: Unstable isotopes of iridium that decay or disintegrate emitting radiation. Ir atoms with atomic weights 182-190, 192, and 194-198 are radioactive iridium isotopes.	3.45	1	1
fluorodeoxyglucose f18 Fluorodeoxyglucose F18: The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162)	4.1	4	0	2-deoxy-2-((18)F)fluoro-D-glucose; 2-deoxy-2-fluoro-aldehydo-D-glucose
dw a 2114r [no description available]	8.67	17	3	platinum coordination entity; pyrrolidines	antineoplastic agent
tetrandrine tetrandrine: a bisbenzylisoquinoline that exhibits antifibrogenic activity	7.04	1	0	bisbenzylisoquinoline alkaloid; isoquinolines
uftoral UFT(R) drug: a drug containing tegafur and uracil; a biochemical modulator of 5-fluorouracil; used for postoperative chemotherapy of colon cancer; reported to cause severe liver injury; do not confuse with 1-UFT protocol	2.01	1	0
ramosetron [no description available]	2.02	1	0	indoles
monochlorobimane monochlorobimane: marker for glutathione	1.98	1	0	organochlorine compound; pyrazolopyrazole	fluorochrome
bis-neodecanoato-1,2-diaminocyclohexaneplatinum(ii) [no description available]	3.08	1	0
gefitinib [no description available]	8.43	1	1	aromatic ether; monochlorobenzenes; monofluorobenzenes; morpholines; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
methotrexate [no description available]	3.13	5	0	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent
docetaxel anhydrous Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.	14.99	77	24	secondary alpha-hydroxy ketone; tetracyclic diterpenoid	antimalarial; antineoplastic agent; photosensitizing agent
hydroxyl radical Hydroxyl Radical: The univalent radical OH. Hydroxyl radical is a potent oxidizing agent.	2.05	1	0	oxygen hydride; oxygen radical; reactive oxygen species
ampelopsin ampelopsin: hepatoprotective agent; isolated from Hovenia dulcis; RN given for (2R-trans)-isomer; structure in first source. (+)-dihydromyricetin : An optically active form of dihydromyricetin having (2R,3R)-configuration.	2.11	1	0	dihydromyricetin; secondary alpha-hydroxy ketone	antineoplastic agent; antioxidant; metabolite
angiotensin ii Giapreza: injectable form of angiotensin II used to increase blood pressure in adult patients with septic or other distributive shock. Ile(5)-angiotensin II : An angiotensin II that acts on the central nervous system (PDB entry: 1N9V).	1.98	1	0	amino acid zwitterion; angiotensin II	human metabolite
dn 108 DN 108: RN & structure in first source	2	1	0
carboplatin [no description available]	13.81	83	8
bradykinin [no description available]	1.99	1	0	oligopeptide	human blood serum metabolite; vasodilator agent
fosfomycin Fosfomycin: An antibiotic produced by Streptomyces fradiae.. fosfomycin : A phosphonic acid having an (R,S)-1,2-epoxypropyl group attached to phosphorus.	7.02	1	0	epoxide; phosphonic acids	antimicrobial agent; EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor
sesquiterpenes [no description available]	2.41	1	0
u 0126 U 0126: protein kinase kinase inhibitor; structure in first source	2.11	1	0	aryl sulfide; dinitrile; enamine; substituted aniline	antineoplastic agent; antioxidant; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; osteogenesis regulator; vasoconstrictor agent
amrubicin amrubicin: structure in first source; a 9-amino-anthracycline antibiotic. amrubicin : A synthetic anthracycline antibiotic with molecular formula C25H25NO9. A specific inhibitor of topoisomerase II, it is used (particularly as the hydrochloride salt) in the treatment of cancer, especially lung cancer, where it is a prodrug for the active metabolite, ambrucinol.	8.48	1	1	anthracycline antibiotic; methyl ketone; primary amino compound; quinone; tetracenes	antineoplastic agent; prodrug; topoisomerase II inhibitor
calixarenes Calixarenes: Phenolic metacyclophanes derived from condensation of PHENOLS and ALDEHYDES. The name derives from the vase-like molecular structures. A bracketed [n] indicates the number of aromatic rings.. calixarenes : Originally macrocyclic compounds capable of assuming a basket (or "calix") shaped conformation. They are formed from p-hydrocarbyl phenols and formaldehyde. The term now applies to a variety of derivatives by substitution of the hydrocarbon cyclo{oligo[(1,3-phenylene)methylene]}.. calixarene : A macrocycle composed of 1,3-phenylene groups linked by methylene groups. The number of 1,3-phenylene units in the macrocycle is denoted by the "n" in calix[n]arene name.	2.17	1	0
granisetron Granisetron: A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic for cancer chemotherapy patients.. granisetron : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of 1-methyl-1H-indazole-3-carboxylic acid with the primary amino group of (3-endo)-9-methyl-9-azabicyclo[3.3.1]nonan-3-amine. A selective 5-HT3 receptor antagonist, it is used (generally as the monohydrochloride salt) to manage nausea and vomiting caused by cancer chemotherapy and radiotherapy, and to prevent and treat postoperative nausea and vomiting.	3.41	1	1	aromatic amide; indazoles
selenium Selenium: An element with the atomic symbol Se, atomic number 34, and atomic weight 78.97. It is an essential micronutrient for mammals and other animals but is toxic in large amounts. Selenium protects intracellular structures against oxidative damage. It is an essential component of GLUTATHIONE PEROXIDASE.	2.21	1	0	chalcogen; nonmetal atom	micronutrient
bafilomycin a1 bafilomycin A1: from Streptomyces griseus; structure given in first source. bafilomycin A1 : The most used of the bafilomycins, a family of toxic macrolide antibiotics derived from Streptomyces griseus.	2.11	1	0	cyclic hemiketal; macrolide antibiotic; oxanes	apoptosis inducer; autophagy inhibitor; bacterial metabolite; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; EC 3.6.3.14 (H(+)-transporting two-sector ATPase) inhibitor; ferroptosis inhibitor; fungicide; potassium ionophore; toxin
peplomycin Peplomycin: An antineoplastic agent derived from BLEOMYCIN.	10.4	4	1	glycopeptide
gadolinium dtpa Gadolinium DTPA: A complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid (DTPA see PENTETIC ACID), that is given to enhance the image in cranial and spinal MRIs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p706)	2.57	2	0	gadolinium coordination entity	MRI contrast agent
enloplatin enloplatin: structure given in first source	3.08	1	0
ski 2053r SKI 2053R: structure in first source; RN given in first source	2.17	1	0
taxane taxane: produced by Taxomyces andreanae	2.42	2	0	diterpene; terpenoid fundamental parent
k201 compound K201 compound: structure given in first source	2	1	0
pirarubicin [no description available]	2.44	2	0	anthracycline
chitosan [no description available]	7.31	1	0
olaparib [no description available]	7.25	1	0	cyclopropanes; monofluorobenzenes; N-acylpiperazine; phthalazines	antineoplastic agent; apoptosis inducer; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
s 1 (combination) S 1 (combination): consists of tegafur, 5-chloro-2,4-dihydroxyuridine & potassium oxonate; an inhibitor of fluorouracil(5-FU) degradation; prolongs the blood 5-FU level as well as increases selective toxicity to tumor; used for the treatment of colon cancer	9.02	27	8
nk 121 NK 121: structure given in first source	7.94	15	2
oligomycins Oligomycins: A closely related group of toxic substances elaborated by various strains of Streptomyces. They are 26-membered macrolides with lactone moieties and double bonds and inhibit various ATPases, causing uncoupling of phosphorylation from mitochondrial respiration. Used as tools in cytochemistry. Some specific oligomycins are RUTAMYCIN, peliomycin, and botrycidin (formerly venturicidin X).	2.13	1	0
levoleucovorin Levoleucovorin: A folate analog consisting of the pharmacologically active isomer of LEUCOVORIN.. (6S)-5-formyltetrahydrofolic acid : The pharmacologically active (6S)-stereoisomer of 5-formyltetrahydrofolic acid.	4.9	4	2	5-formyltetrahydrofolic acid	antineoplastic agent; metabolite
guanine [no description available]	3.87	2	1	2-aminopurines; oxopurine; purine nucleobase	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
3-methyladenine N3-methyladenine: structure in first source	2.11	1	0
raltitrexed [no description available]	8.64	1	1	N-acyl-amino acid
pemetrexed pemetrexed disodium : An organic sodium salt that is the disodium salt of N-{4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid. Inhibits thymidylate synthase (TS), 421 dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT).	6.1	5	2	N-acyl-L-glutamic acid; pyrrolopyrimidine	antimetabolite; antineoplastic agent; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; EC 2.1.1.45 (thymidylate synthase) inhibitor; EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor
aprepitant Aprepitant: A morpholine neurokinin-1 (NK1) receptor antagonist that is used in the management of nausea and vomiting caused by DRUG THERAPY, and for the prevention of POSTOPERATIVE NAUSEA AND VOMITING.. aprepitant : A morpholine-based antiemetic, which is or the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors.	7.53	2	0	(trifluoromethyl)benzenes; cyclic acetal; morpholines; triazoles	antidepressant; antiemetic; neurokinin-1 receptor antagonist; peripheral nervous system drug; substance P receptor antagonist
fosaprepitant fosaprepitant: a pro-drug form of aprepitant. fosaprepitant : A morpholine derivative that is the (1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl ether of (3-{[(2R,3S)-3-(4-fluorophenyl)-2-hydroxymorpholin-4-yl]methyl}-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)phosphonic acid.	2.15	1	0	(trifluoromethyl)benzenes; cyclic acetal; morpholines; phosphoramide; triazoles	antiemetic; neurokinin-1 receptor antagonist; prodrug

Condition	Relationship Strength	Studies	Trials
Congenital Zika Syndrome [description not available]	2.25	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.73	3	0
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	2.25	1	0
Pleural Effusion, Malignant Presence of fluid in the PLEURAL CAVITY as a complication of malignant disease. Malignant pleural effusions often contain actual malignant cells.	3.92	2	1
Abnormalities, Autosome [description not available]	2.54	2	0
Esophageal Squamous Cell Carcinoma A carcinoma that originates usually from cells on the surface of the middle and lower third of the ESOPHAGUS. Tumor cells exhibit typical squamous morphology and form large polypoid lesions. Mutations in RNF6, LZTS1, TGFBR2, DEC1, and WWOX1 genes are associated with this cancer.	8.64	20	8
Cancer of Esophagus [description not available]	15.69	133	32
Esophageal Neoplasms Tumors or cancer of the ESOPHAGUS.	15.69	133	32
Cancer of Cervix [description not available]	13.29	76	30
Exanthem [description not available]	2.41	1	0
Hyperglycemia, Postprandial Abnormally high BLOOD GLUCOSE level after a meal.	2.41	1	0
Emesis [description not available]	7.35	15	8
Colicky Pain [description not available]	2.41	1	0
Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX.	13.29	76	30
Diarrhea An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.	6.93	7	4
Exanthema Diseases in which skin eruptions or rashes are a prominent manifestation. Classically, six such diseases were described with similar rashes; they were numbered in the order in which they were reported. Only the fourth (Duke's disease), fifth (ERYTHEMA INFECTIOSUM), and sixth (EXANTHEMA SUBITUM) numeric designations survive as occasional synonyms in current terminology.	2.41	1	0
Hyperglycemia Abnormally high BLOOD GLUCOSE level.	2.41	1	0
Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.	16.96	34	22
Vomiting The forcible expulsion of the contents of the STOMACH through the MOUTH.	7.35	15	8
Abdominal Pain Sensation of discomfort, distress, or agony in the abdominal region.	2.41	1	0
Nasopharyngeal Carcinoma A carcinoma that originates in the EPITHELIUM of the NASOPHARYNX and includes four subtypes: keratinizing squamous cell, non-keratinizing, basaloid squamous cell, and PAPILLARY ADENOCARCINOMA. It is most prevalent in Southeast Asian populations and is associated with EPSTEIN-BARR VIRUS INFECTIONS. Somatic mutations associated with this cancer have been identified in NPCR, BAP1, UBAP1, ERBB2, ERBB3, MLL2, PIK3CA, KRAS, NRAS, and ARID1A genes.	6.94	21	3
Cancer of Nasopharynx [description not available]	11.88	39	16
Local Neoplasm Recurrence [description not available]	13.38	57	18
Nasopharyngeal Neoplasms Tumors or cancer of the NASOPHARYNX.	11.88	39	16
Carcinoma, Epidermoid [description not available]	17.33	181	60
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	17.33	181	60
Cancer of Ovary [description not available]	8.93	31	8
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	8.93	31	8
Agranulocytosis A decrease in the number of GRANULOCYTES; (BASOPHILS; EOSINOPHILS; and NEUTROPHILS).	2.41	1	0
Carcinoma, Non-Small Cell Lung [description not available]	14.49	61	34
Cancer of Lung [description not available]	15.85	105	46
Thrombopenia [description not available]	11.55	31	16
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	14.49	61	34
Lung Neoplasms Tumors or cancer of the LUNG.	15.85	105	46
Thrombocytopenia A subnormal level of BLOOD PLATELETS.	11.55	31	16
Carcinoma, Anaplastic [description not available]	8.53	19	5
Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.	8.53	19	5
Hepatocellular Carcinoma [description not available]	7.81	3	0
Cancer of Liver [description not available]	6.55	17	3
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	2.81	3	0
Liver Neoplasms Tumors or cancer of the LIVER.	6.55	17	3
Benign Neoplasms [description not available]	7.04	11	3
Cachexia General ill health, malnutrition, and weight loss, usually associated with chronic disease.	2.6	1	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	7.04	11	3
Febrile Neutropenia Fever accompanied by a significant reduction in the number of NEUTROPHILS.	7.6	1	0
Bladder Cancer [description not available]	11.38	11	4
Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER.	6.38	11	4
Carcinoma, Transitional Cell A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.	5.73	7	3
Cancer of the Thyroid [description not available]	2.6	1	0
Thyroid Neoplasms Tumors or cancer of the THYROID GLAND.	2.6	1	0
Lung Adenocarcinoma [description not available]	3.98	2	1
Adenocarcinoma of Lung A carcinoma originating in the lung and the most common lung cancer type in never-smokers. Malignant cells exhibit distinct features such as glandular epithelial, or tubular morphology. Mutations in KRAS, EGFR, BRAF, and ERBB2 genes are associated with this cancer.	3.98	2	1
Lymph Node Metastasis [description not available]	14.5	33	8
Blood Clot [description not available]	2.25	1	0
Thrombosis Formation and development of a thrombus or blood clot in the blood vessel.	2.25	1	0
Allergy, Drug [description not available]	3.22	5	0
Peritoneal Carcinomatosis [description not available]	2.78	3	0
Cancer of the Fallopian Tube [description not available]	2.78	3	0
Drug Hypersensitivity Immunologically mediated adverse reactions to medicinal substances used legally or illegally.	3.22	5	0
Fallopian Tube Neoplasms Benign or malignant neoplasms of the FALLOPIAN TUBES. They are uncommon. If they develop, they may be located in the wall or within the lumen as a growth attached to the wall by a stalk.	2.78	3	0
Peritoneal Neoplasms Tumors or cancer of the PERITONEUM.	2.78	3	0
Hyperammonemia Elevated level of AMMONIA in the blood. It is a sign of defective CATABOLISM of AMINO ACIDS or ammonia to UREA.	8.17	1	0
Cancer of Head [description not available]	11.37	35	15
Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)	11.37	35	15
Disease Exacerbation [description not available]	8.34	11	7
Cryptogenic Fibrosing Alveolitis [description not available]	2.31	1	0
Carcinoma, Small Cell Lung [description not available]	5.44	7	2
Breathlessness [description not available]	2.31	1	0
Dyspnea Difficult or labored breathing.	2.31	1	0
Idiopathic Pulmonary Fibrosis A common interstitial lung disease of unknown etiology, usually occurring between 50-70 years of age. Clinically, it is characterized by an insidious onset of breathlessness with exertion and a nonproductive cough, leading to progressive DYSPNEA. Pathological features show scant interstitial inflammation, patchy collagen fibrosis, prominent fibroblast proliferation foci, and microscopic honeycomb change.	2.31	1	0
Small Cell Lung Carcinoma A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).	5.44	7	2
Bone Marrow Diseases Diseases involving the BONE MARROW.	3.53	1	1
Leukocytopenia [description not available]	8.9	22	11
Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000).	8.9	22	11
Sarcopenia Progressive decline in muscle mass due to aging which results in decreased functional capacity of muscles.	2.17	1	0
Adenocarcinoma, Endometrioid [description not available]	2.15	1	0
Atrial Ectopic Beats [description not available]	2.15	1	0
Cardiac Toxicity [description not available]	2.15	1	0
Adenocarcinoma, Basal Cell [description not available]	10.55	40	20
Arrhythmia [description not available]	7.15	1	0
Sinus Tachycardia [description not available]	2.15	1	0
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	10.55	40	20
Arrhythmias, Cardiac Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.	2.15	1	0
Carcinoma, Endometrioid An adenocarcinoma characterized by the presence of cells resembling the glandular cells of the ENDOMETRIUM. It is a common histological type of ovarian CARCINOMA and ENDOMETRIAL CARCINOMA. There is a high frequency of co-occurrence of this form of adenocarcinoma in both tissues.	2.15	1	0
Cardiotoxicity Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.	2.15	1	0
Thromboembolism, Venous [description not available]	2.17	1	0
Venous Thromboembolism Obstruction of a vein or VEINS (embolism) by a blood clot (THROMBUS) in the blood stream.	2.17	1	0
Cancer of Granulosa Cells [description not available]	2.17	1	0
Ascites Accumulation or retention of free fluid within the peritoneal cavity.	2.52	2	0
Carcinoma, Squamous Cell of Head and Neck [description not available]	4.41	4	1
Cancer of Larynx [description not available]	3.44	7	0
Cancer of Mouth [description not available]	8.68	24	8
Cancer of Pharynx [description not available]	2.42	2	0
Squamous Cell Carcinoma of Head and Neck The most common type of head and neck carcinoma that originates from cells on the surface of the NASAL CAVITY; MOUTH; PARANASAL SINUSES, SALIVARY GLANDS, and LARYNX. Mutations in TNFRSF10B, PTEN, and ING1 genes are associated with this cancer.	4.41	4	1
Laryngeal Neoplasms Cancers or tumors of the LARYNX or any of its parts: the GLOTTIS; EPIGLOTTIS; LARYNGEAL CARTILAGES; LARYNGEAL MUSCLES; and VOCAL CORDS.	3.44	7	0
Mouth Neoplasms Tumors or cancer of the MOUTH.	8.68	24	8
Pharyngeal Neoplasms Tumors or cancer of the PHARYNX.	2.42	2	0
Carcinosarcoma A malignant neoplasm that contains elements of carcinoma and sarcoma so extensively intermixed as to indicate neoplasia of epithelial and mesenchymal tissue. (Stedman, 25th ed)	3.01	1	0
Recrudescence [description not available]	7.99	18	3
Cancer, Embryonal [description not available]	6.05	10	3
Cancer of Testis [description not available]	7.5	14	4
Neoplasms, Germ Cell and Embryonal Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS.	6.05	10	3
Testicular Neoplasms Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.	7.5	14	4
Mucositis An INFLAMMATION of the MUCOSA with burning or tingling sensation. It is characterized by atrophy of the squamous EPITHELIUM, vascular damage, inflammatory infiltration, and ulceration. It usually occurs at the mucous lining of the MOUTH, the GASTROINTESTINAL TRACT or the airway due to chemical irritations, CHEMOTHERAPY, or radiation therapy (RADIOTHERAPY).	2.47	2	0
Epithelial Ovarian Cancer [description not available]	2.48	2	0
Epithelial Neoplasms [description not available]	2.48	2	0
Carcinoma, Ovarian Epithelial A malignant neoplasm that originates in cells on the surface EPITHELIUM of the ovary and is the most common form of ovarian cancer. There are five histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Mutations in BRCA1, OPCML, PRKN, PIK3CA, AKT1, CTNNB1, RRAS2, and CDH1 genes are associated with this cancer.	2.48	2	0
Bone Cancer [description not available]	4.71	3	2
Metastase [description not available]	8.29	9	3
Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES.	4.71	3	2
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	8.29	9	3
Neutropenia A decrease in the number of NEUTROPHILS found in the blood.	11.45	31	25
Carcinoma, Thymic [description not available]	3	1	0
Thymoma A neoplasm originating from thymic tissue, usually benign, and frequently encapsulated. Although it is occasionally invasive, metastases are extremely rare. It consists of any type of thymic epithelial cell as well as lymphocytes that are usually abundant. Malignant lymphomas that involve the thymus, e.g., lymphosarcoma, Hodgkin's disease (previously termed granulomatous thymoma), should not be regarded as thymoma. (From Stedman, 25th ed)	3	1	0
Anemia A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.	9.59	12	11
EBV Infections [description not available]	2.1	1	0
Epstein-Barr Virus Infections Infection with human herpesvirus 4 (HERPESVIRUS 4, HUMAN); which may facilitate the development of various lymphoproliferative disorders. These include BURKITT LYMPHOMA (African type), INFECTIOUS MONONUCLEOSIS, and oral hairy leukoplakia (LEUKOPLAKIA, HAIRY).	2.1	1	0
HPV Infection [description not available]	2.1	1	0
Cancer of Oropharnyx [description not available]	3.3	6	0
Oropharyngeal Neoplasms Tumors or cancer of the OROPHARYNX.	3.3	6	0
Papillomavirus Infections Neoplasms of the skin and mucous membranes caused by papillomaviruses. They are usually benign but some have a high risk for malignant progression.	2.1	1	0
Female Genital Neoplasms [description not available]	7.5	11	3
Genital Neoplasms, Female Tumor or cancer of the female reproductive tract (GENITALIA, FEMALE).	7.5	11	3
Cancer of the Ureter [description not available]	5.47	5	1
Ureteral Neoplasms Cancer or tumors of the URETER which may cause obstruction leading to hydroureter, HYDRONEPHROSIS, and PYELONEPHRITIS. HEMATURIA is a common symptom.	5.47	5	1
Acute Kidney Failure [description not available]	4.41	2	2
Alopecia Cicatrisata [description not available]	5.71	5	4
Alopecia Absence of hair from areas where it is normally present.	5.71	5	4
Carcinoma, Large Cell A tumor of undifferentiated (anaplastic) cells of large size. It is usually bronchogenic. (From Dorland, 27th ed)	3.87	2	1
Acute Kidney Injury Abrupt reduction in kidney function. Acute kidney injury encompasses the entire spectrum of the syndrome including acute kidney failure; ACUTE KIDNEY TUBULAR NECROSIS; and other less severe conditions.	4.41	2	2
Hemorrhage, Uterine [description not available]	2.11	1	0
Cancer of the Vagina [description not available]	2.11	1	0
Uterine Hemorrhage Bleeding from blood vessels in the UTERUS, sometimes manifested as vaginal bleeding.	2.11	1	0
Vaginal Neoplasms Tumors or cancer of the VAGINA.	2.11	1	0
Blood Diseases [description not available]	4.89	4	2
Hematologic Diseases Disorders of the blood and blood forming tissues.	4.89	4	2
Cancer of Nose [description not available]	2.11	1	0
Cancer of Paranasal Sinus [description not available]	2.11	1	0
Paranasal Sinus Neoplasms Tumors or cancer of the PARANASAL SINUSES.	2.11	1	0
Cancer of the Urinary Tract [description not available]	4.88	4	2
Injuries, Radiation [description not available]	4.45	2	2
Enteritis Inflammation of any segment of the SMALL INTESTINE.	3.5	1	1
Neoplasms, Cystic, Mucinous, and Serous Neoplasms containing cyst-like formations or producing mucin or serum.	2.11	1	0
Experimental Lung Inflammation Inflammation of any part, segment or lobe, of the lung parenchyma.	3.5	1	1
Mucositis, Oral [description not available]	5.84	4	2
Esophagitis INFLAMMATION, acute or chronic, of the ESOPHAGUS caused by BACTERIA, chemicals, or TRAUMA.	8.01	6	5
Pneumonia Infection of the lung often accompanied by inflammation.	3.5	1	1
Stomatitis INFLAMMATION of the soft tissues of the MOUTH, such as MUCOSA; PALATE; GINGIVA; and LIP.	5.84	4	2
Breast Cancer [description not available]	10.41	5	1
Breast Neoplasms Tumors or cancer of the human BREAST.	5.41	5	1
Maxillary Neoplasms Cancer or tumors of the MAXILLA or upper jaw.	2.49	2	0
Cancer of the Urethra [description not available]	3.45	2	0
Urethral Neoplasms Cancer or tumors of the URETHRA. Benign epithelial tumors of the urethra usually consist of squamous and transitional cells. Primary urethral carcinomas are rare and typically of squamous cells. Urethral carcinoma is the only urological malignancy that is more common in females than in males.	3.45	2	0
Carcinoma, Papillary A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)	2.13	1	0
Cystadenocarcinoma, Serous A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)	2.43	2	0
Minimal Disease, Residual [description not available]	2.13	1	0
Acute Autoimmune Neuropathy [description not available]	2.13	1	0
Paralysis, Legs [description not available]	2.13	1	0
Intradural-Extramedullary Spinal Cord Neoplasms [description not available]	2.13	1	0
Paraplegia Severe or complete loss of motor function in the lower extremities and lower portions of the trunk. This condition is most often associated with SPINAL CORD DISEASES, although BRAIN DISEASES; PERIPHERAL NERVOUS SYSTEM DISEASES; NEUROMUSCULAR DISEASES; and MUSCULAR DISEASES may also cause bilateral leg weakness.	2.13	1	0
Spinal Cord Neoplasms Benign and malignant neoplasms which occur within the substance of the spinal cord (intramedullary neoplasms) or in the space between the dura and spinal cord (intradural extramedullary neoplasms). The majority of intramedullary spinal tumors are primary CNS neoplasms including ASTROCYTOMA; EPENDYMOMA; and LIPOMA. Intramedullary neoplasms are often associated with SYRINGOMYELIA. The most frequent histologic types of intradural-extramedullary tumors are MENINGIOMA and NEUROFIBROMA.	2.13	1	0
Guillain-Barre Syndrome An acute inflammatory autoimmune neuritis caused by T cell- mediated cellular immune response directed towards peripheral myelin. Demyelination occurs in peripheral nerves and nerve roots. The process is often preceded by a viral or bacterial infection, surgery, immunization, lymphoma, or exposure to toxins. Common clinical manifestations include progressive weakness, loss of sensation, and loss of deep tendon reflexes. Weakness of respiratory muscles and autonomic dysfunction may occur. (From Adams et al., Principles of Neurology, 6th ed, pp1312-1314)	2.13	1	0
Kidney Diseases Pathological processes of the KIDNEY or its component tissues.	2.94	4	0
Sertoli Cell Tumor Gonadal neoplasm composed entirely of SERTOLI CELLS or may have a component of GRANULOSA CELLS. Some of the Sertoli cell tumors produce ESTROGEN or ANDROGENS, but seldom in sufficient quantity to cause clinical symptoms such as FEMINIZATION or masculinization (VIRILISM).	2.04	1	0
Carcinoma, Oat Cell [description not available]	6.93	9	2
Cancer of Gallbladder [description not available]	2.04	1	0
Gallbladder Neoplasms Tumors or cancer of the gallbladder.	2.04	1	0
Carcinoma, Small Cell An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)	6.93	9	2
Neoplasm Metastasis, Unknown Primary [description not available]	2.44	2	0
Tumour Lysis Syndrome [description not available]	2.04	1	0
Tumor Lysis Syndrome A syndrome resulting from cytotoxic therapy, occurring generally in aggressive, rapidly proliferating lymphoproliferative disorders. It is characterized by combinations of hyperuricemia, lactic acidosis, hyperkalemia, hyperphosphatemia and hypocalcemia.	2.04	1	0
Cancer of Pancreas [description not available]	2.44	2	0
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	2.44	2	0
Gastric Fistula Abnormal passage communicating with the STOMACH.	2.05	1	0
Lymphatic Diseases Diseases of LYMPH; LYMPH NODES; or LYMPHATIC VESSELS.	2.05	1	0
Hypopharyngeal Cancer [description not available]	3.15	5	0
Multiple Primary Neoplasms [description not available]	2.72	3	0
Hypopharyngeal Neoplasms Tumors or cancer of the HYPOPHARYNX.	3.15	5	0
Anorexia The lack or loss of APPETITE accompanied by an aversion to food and the inability to eat. It is the defining characteristic of the disorder ANOREXIA NERVOSA.	7.62	9	7
Benign Neoplasms, Brain [description not available]	4.33	4	1
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	4.33	4	1
Cancer of the Tongue [description not available]	2.95	4	0
Tongue Neoplasms Tumors or cancer of the TONGUE.	2.95	4	0
Cancer of Stomach [description not available]	5.46	8	2
Stomach Neoplasms Tumors or cancer of the STOMACH.	5.46	8	2
Neoplasms, Squamous Cell Neoplasms of the SQUAMOUS EPITHELIAL CELLS. The concept does not refer to neoplasms located in tissue composed of squamous elements.	4.41	2	2
Cardiovascular Stroke [description not available]	2.05	1	0
Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).	2.05	1	0
Dysmyelopoietic Syndromes [description not available]	2.05	1	0
Acute Myelogenous Leukemia [description not available]	2.05	1	0
Cancer, Second Primary [description not available]	2.05	1	0
Myelodysplastic Syndromes Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.	2.05	1	0
Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.	2.05	1	0
Antidiuretic Hormone, Inappropriate Secretion [description not available]	2.05	1	0
Inappropriate ADH Syndrome A condition of HYPONATREMIA and renal salt loss attributed to overexpansion of BODY FLUIDS resulting from sustained release of ANTIDIURETIC HORMONES which stimulates renal resorption of water. It is characterized by normal KIDNEY function, high urine OSMOLALITY, low serum osmolality, and neurological dysfunction. Etiologies include ADH-producing neoplasms, injuries or diseases involving the HYPOTHALAMUS, the PITUITARY GLAND, and the LUNG. This syndrome can also be drug-induced.	2.05	1	0
Cancer of Kidney [description not available]	5.26	4	1
Kidney Neoplasms Tumors or cancers of the KIDNEY.	5.26	4	1
Kidney Failure A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.	2.06	1	0
Renal Insufficiency Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.	2.06	1	0
Adrenal Cancer [description not available]	2.97	1	0
Nephrotic Syndrome A condition characterized by severe PROTEINURIA, greater than 3.5 g/day in an average adult. The substantial loss of protein in the urine results in complications such as HYPOPROTEINEMIA; generalized EDEMA; HYPERTENSION; and HYPERLIPIDEMIAS. Diseases associated with nephrotic syndrome generally cause chronic kidney dysfunction.	7.06	1	0
Liver Dysfunction [description not available]	7.06	1	0
Liver Diseases Pathological processes of the LIVER.	2.06	1	0
Adenocarcinoma, Clear Cell An adenocarcinoma characterized by the presence of varying combinations of clear and hobnail-shaped tumor cells. There are three predominant patterns described as tubulocystic, solid, and papillary. These tumors, usually located in the female reproductive organs, have been seen more frequently in young women since 1970 as a result of the association with intrauterine exposure to diethylstilbestrol. (From Holland et al., Cancer Medicine, 3d ed)	4.1	3	1
Carcinoma, Neuroendocrine A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round blue cells, granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small (oat) cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)	2.07	1	0
Carcinoma, Adenosquamous A mixed adenocarcinoma and squamous cell or epidermoid carcinoma.	5.43	5	3
Allergic Reaction [description not available]	2.08	1	0
Hypersensitivity Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen.	7.08	1	0
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	2.07	1	0
Weight Reduction [description not available]	2.43	2	0
Weight Loss Decrease in existing BODY WEIGHT.	2.43	2	0
Experimental Hepatoma [description not available]	2.07	1	0
Intestinal Perforation Opening or penetration through the wall of the INTESTINES.	2.07	1	0
Genetic Predisposition [description not available]	2.08	1	0
Anal Cancer [description not available]	2.44	2	0
Anus Neoplasms Tumors or cancer of the ANAL CANAL.	2.44	2	0
Cancer of Pelvis [description not available]	2.08	1	0
Joint Pain [description not available]	2.01	1	0
Arthralgia Pain in the joint.	2.01	1	0
Cancer of Colon [description not available]	4.62	3	2
Colonic Neoplasms Tumors or cancer of the COLON.	4.62	3	2
Malignant Melanoma [description not available]	2.4	2	0
Cancer of Rectum [description not available]	2.01	1	0
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	2.4	2	0
Rectal Neoplasms Tumors or cancer of the RECTUM.	2.01	1	0
Tracheal Neoplasms New abnormal growth of tissue in the TRACHEA.	2.41	2	0
Adenocystic Carcinoma [description not available]	2.41	2	0
Carcinoma, Adenoid Cystic Carcinoma characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells. When the cylinders occur within masses of epithelial cells, they give the tissue a perforated, sievelike, or cribriform appearance. Such tumors occur in the mammary glands, the mucous glands of the upper and lower respiratory tract, and the salivary glands. They are malignant but slow-growing, and tend to spread locally via the nerves. (Dorland, 27th ed)	2.41	2	0
Congenital Epulides [description not available]	2.42	2	0
Weight Gain Increase in BODY WEIGHT over existing weight.	2.02	1	0
Acute Kidney Tubular Necrosis [description not available]	2.02	1	0
Kidney Tubular Necrosis, Acute Acute kidney failure resulting from destruction of EPITHELIAL CELLS of the KIDNEY TUBULES. It is commonly attributed to exposure to toxic agents or renal ISCHEMIA following severe TRAUMA.	2.02	1	0
Cancer of the Thymus [description not available]	2.42	2	0
Thymus Neoplasms Tumors or cancer of the THYMUS GLAND.	2.42	2	0
Anticipatory Vomiting [description not available]	5.42	5	3
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	2.93	4	0
Proteinuria The presence of proteins in the urine, an indicator of KIDNEY DISEASES.	2.02	1	0
Chronic Kidney Failure [description not available]	2.7	3	0
Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.	2.7	3	0
Glycosuria The appearance of an abnormally large amount of GLUCOSE in the urine, such as more than 500 mg/day in adults. It can be due to HYPERGLYCEMIA or genetic defects in renal reabsorption (RENAL GLYCOSURIA).	2.02	1	0
Invasiveness, Neoplasm [description not available]	2.43	2	0
Adenoma, Pleomorphic A benign, slow-growing tumor, most commonly of the salivary gland, occurring as a small, painless, firm nodule, usually of the parotid gland, but also found in any major or accessory salivary gland anywhere in the oral cavity. It is most often seen in women in the fifth decade. Histologically, the tumor presents a variety of cells: cuboidal, columnar, and squamous cells, showing all forms of epithelial growth. (Dorland, 27th ed)	2.03	1	0
Enterocolitis, Neutropenic A syndrome characterized by inflammation in the ILEUM, the CECUM, and the ASCENDING COLON. It is observed in cancer patients with CHEMOTHERAPY-induced NEUTROPENIA or in other immunocompromised individuals (IMMUNOCOMPROMISED HOST).	2.03	1	0
Retroperitoneal Neoplasms New abnormal growth of tissue in the RETROPERITONEAL SPACE.	2.03	1	0
Cancer of the Uterus [description not available]	4.85	4	2
Uterine Neoplasms Tumors or cancer of the UTERUS.	4.85	4	2
Adverse Drug Event [description not available]	3.35	2	0
Drug-Related Side Effects and Adverse Reactions Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.	3.35	2	0
Odontogenic Cyst, Calcifying A mixed radiolucent-radiopaque lesion of the jaws with features of both a cyst and a solid neoplasm. It is characterized microscopically by an epithelial lining showing a palisaded layer of columnar basal cells, presence of ghost cell keratinization, dentinoid, and calcification. (Stedman, 25th ed)	2.03	1	0
Mandibular Neoplasms Tumors or cancer of the MANDIBLE.	2.03	1	0
Acute Liver Injury, Drug-Induced [description not available]	3.43	1	1
Pyrexia [description not available]	3.43	1	1
Fever An abnormal elevation of body temperature, usually as a result of a pathologic process.	3.43	1	1
Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.	3.43	1	1
B16 Melanoma [description not available]	3.37	1	1
Cancer of Skin [description not available]	3.37	1	1
Skin Neoplasms Tumors or cancer of the SKIN.	3.37	1	1
Experimental Mammary Neoplasms [description not available]	1.98	1	0
Cancer of Prostate [description not available]	6.29	5	3
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	6.29	5	3
Anesthesia A state characterized by loss of feeling or sensation. This depression of nerve function is usually the result of pharmacologic action and is induced to allow performance of surgery or other painful procedures.	1.98	1	0
Genito-urinary Cancer [description not available]	3.3	2	0
Urogenital Neoplasms Tumors or cancer of the UROGENITAL SYSTEM in either the male or the female.	3.3	2	0
Glial Cell Tumors [description not available]	1.99	1	0
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	1.99	1	0
Teratocarcinoma A malignant neoplasm consisting of elements of teratoma with those of embryonal carcinoma or choriocarcinoma, or both. It occurs most often in the testis. (Dorland, 27th ed)	1.99	1	0
Carcinoma, Lewis Lung A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy.	2.91	4	0
Adenocarcinoma, Papillary An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed)	1.99	1	0
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	1.98	1	0
Leucocythaemia [description not available]	1.97	1	0
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	1.97	1	0
Primary Peritonitis [description not available]	1.97	1	0
Peritonitis INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.	1.97	1	0
Sarcoma 180 An experimental sarcoma of mice.	1.97	1	0
Experimental Neoplasms [description not available]	1.97	1	0
Cystadenocarcinoma A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)	1.97	1	0

nedaplatin

Description

Cross-References

Synonyms (28)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Protein Targets (4)

Potency Measurements

Bioassays (30)

Research

Studies (542)

Market Indicators

Research Demand Index: 36.72

Study Types

Clinical Trials (44)

Trial Overview

nedaplatin

Description

Cross-References

Synonyms (28)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Protein Targets (4)

Potency Measurements

Bioassays (30)

Research

Studies (542)

Market Indicators

Research Demand Index: 36.72

Study Types

Clinical Trials (44)

Trial Overview

Related Drugs (78)

Related Conditions (276)